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ABSTRACT

The abuse of and addiction to drugs of abuse, such as tobacco, alcohol, opioids,
and illicit drugs, are growing global problems that affect the welfare of individuals and
societies worldwide. The National Institute of Drug Abuse estimates the annual cost of
substance abuse to be over $740 billion in costs related to drug intoxication, withdrawal
and relapse. A primary challenge in the treatment of substance abuse is the tendency of
users to relapse following acute or extended periods of abstinence; on average over 60%
of substance abusers will return to drug use within a year of receiving treatment, many
relapsing following stressful life events. Central to the successful treatment of drug
addiction is understanding the cellular mechanisms by which relapse episodes occur.
Current data suggest that the activation of pituitary adenylate cyclase activating peptide
(PACAP) systems in the bed nucleus of the stria terminalis (BNST) is an important event
underlying stress-induced reinstatement to drug-seeking in a rodent model of stressinduced relapse.
In conjunction with immunohistochemistry and pharmacological treatments, we
used this behavioral model of stress-induced relapse to evaluate PACAP and PACAP
type-1 receptor (PAC1-R) signaling in stress-induced reinstatement to cocaine seeking.
Activation of the PAC1 receptor appears to be critical to stress-induced reinstatement, as
the selective PAC1-R agonist, maxadilan, produced reinstatement behaviors in the
absence of stress. Moreover, BNST pretreatment with either mitogen activated protein
kinase-ERK (MEK) or endocytosis inhibitors to block extracellular signal-related kinase
(ERK) signaling attenuated stress-induced reinstatement. Furthermore, BNST
phosphorylated ERK (pERK) expression, mediated by PAC1-R activation, is
substantially potentiated in cocaine-experienced animals after stressor exposure, in a
manner that is dependent on endosomal signaling and MEK activity.
These data suggest that the activation of a PAC1 signaling cascade is a key event
underlying stress-induced reinstatement. Furthermore, this data may suggest a permanent
change in the BNST PACAP system (sensitization) following cocaine exposure.

CITATIONS

Material from this dissertation has been published in the following form:
Miles, Olivia. W., Thrailkill, E.A., Linden, A.K., May, V., Bouton, M.E., & Hammack,
S.E.. (2017). Pituitary Adenylate Cyclase-Activating Peptide in the Bed Nucleus of the
Stria Terminalis Mediates Stress-Induced Reinstatement of Cocaine Seeking in Rats.
Neuropsychopharmacology, 1-9.

ii

ACKNOWLEDGEMENTS
The work presented in this dissertation would not have been possible without the patient
guidance and support of my colleagues, friends, and family. First and foremost, I would
like to thank my advisor, Jom Hammack, for his consistent encouragement and support.
Throughout my graduate studies, Jom has modeled perseverance, commitment to the
pursuit of knowledge, and unending curiosity. I am also greatly appreciative of my
dissertation thesis committee – Drs. Victor May, Mark Bouton, John Green, and Hugh
Garavan – for their scientific advice and thoughtful guidance on my research.

I would also like to thank the Department of Psychological Science program at UVM for
providing a supporting environment and encouraging guidance through all stages of the
PhD process. I have had the privilege to work with an incredible group of young
scientists, and am especially grateful to my undergraduate research assistants, particularly
Michaela O’Reilly, Nicole Liberman, and Sarah Brainard, who provided instrumental
support during the early phases of my research project.

Finally, the support of my family and friends during this process has been truly
invaluable. I am so grateful for the support of my parents, Tom Miles and Alicia
Wuesthoff, my sister Genevieve, and especially Caleb James.

iii

TABLE OF CONTENTS

CITATIONS .................................................................................................................... ii
ACKNOWLEDGEMENTS ............................................................................................ iii
LIST OF FIGURES ...................................................................................................... viii
ABBREVIATIONS ......................................................................................................... x
CHAPTER 1: LITERATURE REVIEW ......................................................................... 1
1.1. General Introduction ........................................................................................... 1
1.2. Neurobiology of “Addiction” ............................................................................. 6
Characterization of Substance Abuse ......................................................................... 6
Development of Addiction........................................................................................... 7
1.3. BNST in Addiction Processes ............................................................................. 12
Norepinephrine and Drug Abuse .............................................................................. 14
The BNST in negative reinforcement processes ....................................................... 16
Anxiety-like Responses in Drug Abuse ..................................................................... 17
Corticotropin Releasing Hormone (CRH) ................................................................ 17
1.4. Pituitary Adenylate Cyclase Activating Peptide (PACAP) ................................. 19
PACAP & PAC1 receptors in emotional behaviors ................................................. 20
PACAP & PAC1 receptors in addiction-releated behaviors .................................... 23
PAC1 signaling through extracellular signaling related kinase (ERK) activation .. 25
1.5 Summary ............................................................................................................... 28
1.6 Figures .................................................................................................................. 30
iv

CHAPTER 2: INTRA-BNST MAXADILAN INFUSION MIMICS STRESSOR
EXPOSURE AND INDUCES REINSTATEMENT OF DRUG-SEEKING
BEHAVIOR ................................................................................................................... 35
2.1. Introduction.......................................................................................................... 35
2.2. Materials & Methods ........................................................................................... 37
2.3. Results ................................................................................................................. 41
2.4. Discussion ............................................................................................................ 45
2.5 Figures .................................................................................................................. 49
CHAPTER 3: COCAINE EXPERIENCE POTENTIATES SHOCK-INDUCED pERK
VIA PAC1 RECEPTOR MECHANISM ....................................................................... 54
3.1. Introduction.......................................................................................................... 54
3.2. Materials & Methods ........................................................................................... 55
3.3. Results ................................................................................................................. 58
3.4. Discussion ............................................................................................................ 62
3.5. Figures ................................................................................................................. 65
CHAPTER 4: BLOCKADE OF CLATHRIN MEDIATED ENDOCYTOSIS BY
PITSTOP2 ATTENUATES STRESS-INDUCED REINSTATEMENT TO COCAINESEEKING ...................................................................................................................... 72
4.1. Introduction.......................................................................................................... 72
4.2. Materials & Methods ........................................................................................... 75

v

4.3. Results ................................................................................................................. 78
4.4. Discussion ............................................................................................................ 82
4.5. Figures ................................................................................................................. 86
CHAPTER 5: INHIBITION OF MEK PATHWAY ATTENUATES STRESSINDUCED REINSTATEMENT TO COCAINE SEEKING. ....................................... 93
5.1. Introduction.......................................................................................................... 93
5.2 Materials & Methods ............................................................................................ 96
5.3. Results ................................................................................................................. 99
5.4. Discussion .......................................................................................................... 103
5.5. Figures ............................................................................................................... 107
CHAPTER 6: GENERAL DISCUSSION ................................................................... 114
6.1. The role of BNST in addiction .......................................................................... 115
BNST afferent signaling .......................................................................................... 116
BNST efferent signaling .......................................................................................... 117
BNST in the Dark Side of Addiction ....................................................................... 119
Considerations from quantitative polymerase chain reaction (qPCR) .................. 123
Considerations from PACAP KO studies ............................................................... 124
6.2. BNST PACAP signaling via ERK ..................................................................... 124
Signaling through extracellular signaling related kinase (ERK) activation .......... 124
ERK activation via AC or PLC ............................................................................... 127
6.3. Relation to human studies and clinical trials ..................................................... 128

vi

6.4. Summary ............................................................................................................ 129
COMPREHENSIVE BIBLIOGRAPHY ..................................................................... 132

vii

LIST OF FIGURES

Figure

Page
Chapter 1

Figure 1.1. Intra-BNST PACAP38 causes reinstatement of extinguished cocaine
seeking. ............................................................................................................................. 30
Figure 1.2. Intra-BNST PACAP antagonist (PACAP6-38) attenuates stressinduced reinstatement in rats. ........................................................................................... 31
Figure 1.3. Cocaine self-administration alters endogenous PACAP levels in the
BNST. ............................................................................................................................... 32
Figure 1.4. PACAP transcript levels after acute cocaine self-administration................... 33
Figure 1.5. Modified schematic of PAC1 receptor signaling cascade .............................. 34
Chapter 2
Figure 2.1. Timeline for Experiment 1. ............................................................................ 49
Figure 2.2. BNST Cannula Placements. ........................................................................... 50
Figure 2.3. Intra-BNST maxadilan infusion induces reinstatement of drug-seeking
in the absence of stressor exposure. .................................................................................. 51
Figure 2.4. Total cocaine infusions over 10d acquisition. ................................................ 53
Chapter 3
Figure 3.1. Timeline for Experiment 2. ............................................................................ 65
Figure 3.2. BNST Cannula Placements. ........................................................................... 66
Figure 3.3. Intra-BNST infusion of PACAP6-38 attenuates stress-induced
reinstatement. .................................................................................................................... 67
Figure 3.4. Total cocaine infusions over 10d acquisition. ................................................ 69
viii

Figure 3.5. PAC1 receptor activation and ERK activation participate in BNSTmediated reinstatement to drug-seeking ........................................................................... 71
Chapter 4
Figure 4.1. Timeline for Experiment 3. ............................................................................ 86
Figure 4.2. BNST Cannula Placements. ........................................................................... 87
Figure 4.3. Intra-BNST Pitstop2 infusion attenuates stress-induced reinstatement to
cocaine-seeking. ................................................................................................................ 88
Figure 4.4. Total cocaine intake over 10d acquisition. ..................................................... 90
Figure 4.5. PACAP receptor internalization and ERK activation participate in BNSTmediated reinstatement to extinguished drug seeking. ..................................................... 92
Chapter 5
Figure 5.1. Timeline for Experiment 4. .......................................................................... 107
Figure 5.2. BNST Cannula Placements. ......................................................................... 108
Figure 5.3. Intra-BNST infusion of MEK Inhibitor PD98059 attenuates stressinduced reinstatement. .................................................................................................... 109
Figure 5.4. Total cocaine intake over 10d acquisition. ................................................... 111
Figure 5.5. BNST pretreatment with MEK inhibitor PD98059 blocks stressinduced ERK phosphorylation. ....................................................................................... 113

ix

ABBREVIATIONS

AC
ANOVA
APA
BLA
BNST
BNSTld
BNSTov
cAMP
CCI
cDNA
CeA
c-fos
CGRP
ChR2
CNS
CPP
Cre
CREB
CRH
CRH-R1
CRH-R2
DA
dBNST
DSM-V
ERK
GABA
GHRH
HEK
HPA
ICSS
ICV
KO
LC
MAPK
Max.d.4
MDD
MEK
mPFC
mRNA
NAcc
NE

Adenylate cyclase
Analysis of Variance
American psychiatric association
Basolateral amygdala
Bed nucleus of the stria terminalis
Dorsolateral region of BNST
Oval nucleus of the BNST
Cyclic adenosine monophosphate
Chronic constriction injury
Complementary deoxyribonucleic acid (DNA)
Central amygdala
Proto-oncogene from Fos family of transcription factors
Calcitonin gene related peptide
Channelrhodopsin
Central nervous system
Conditioned place preference
Cre-recombinase
cAMP response element binding protein
Corticotropin-releasing hormone
Corticotropin-releasing hormone receptor-1
Corticotropin-releasing hormone receptor-2
Dopamine
Dorsal aspect of anterolateral BNST
5th diagnostic and statistical manual of mental disorders
Extracellular signal-related kinase
Gamma-aminobutyric acid
Growth-hormone releasing hormone
Human embryonic kidney cells
Hypothalamic-pituitary-adrenal axis
Intracranial self-stimulation
Intracerebroventricular
Knockout
Locus coeruleus
Mitogen-activated protein kinase cascade
Deletion of 17 amino acids from maxadilan; PAC1 antagonist
Major depressive disorder
MAPK-extracellular signal related kinase
Medial prefrontal cortex
Messenger ribonucleic acid (RNA)
Nucleus accumbens
Norepinephrine
x

NPY
NTS
OCT
PAC1
PACAP
PBn
PD98059
PI-3
PKA
PKC
PLC
PTSD
PVN
SEM
SL327
SNS
vBNST
VIP
VP
VPAC1
VPAC2
VTA

Neuropeptide Y
Nucleus tractus solitarius of the brainstem
Optimal cutting temperature
PACAP type 1 receptor
Pituitary adenylate cyclase activating peptide
Parabrachial nucleus
MEK pathway inhibitor
Phosphoinositide 3-kinase
Protein kinase-A
Protein kinase-C
Phospholipase C
Post-traumatic stress disorder
Paraventricular nucleus of the hypothalamus
Standard error of the mean
MEK pathway inhibitor
Sympathetic nervous system
Ventral region of the anterolateral BNST
Vasoactive intestinal peptide
Ventral pallidum
Vasoactive intestinal polypeptide receptor 1
Vasoactive intestinal polypeptide receptor 2
Ventral tegmental area

xi

CHAPTER 1: LITERATURE REVIEW

1.1. General Introduction
The abuse of and addiction to drugs of abuse, such as tobacco, alcohol, opioids, and
illicit drugs is a growing global problem that affects the welfare of individuals and
societies worldwide. Indeed, substance abuse is costly to the Unites States: the National
Institute of Drug Abuse estimates expenditures of $740 billion annually on costs related
to drug intoxication, withdrawal, relapse (Feit & Taylor, 2015), and the consequences
of this chronic cycle.

A primary challenge in the treatment of substance abuse is the tendency of users to
relapse following acute or extended periods of abstinence. On average, over 60% of
substance abusers will return to drug use within a year of receiving treatment (Scott et
al., 2011; Higgins et al., 2012). Although many factors may contribute to drug relapse,
one critical factor may be exposure to a stressor (Sinha et al., 2006). Relapse rates are
often higher following stressful events (Breese et al., 2011). In laboratory settings,
stressors can produce the “reinstatement” of drug-seeking behaviors following periods
of abstinence. In a standard stress-induced reinstatement procedure (discussed in detail
below), rats self-administer cocaine via lever-press response, and then have the
behavior extinguished, where subsequent lever presses no longer deliver cocaine. After
extinction, exposure to a stressor (i.e. unpredictable footshock) can reinstate drugseeking on the lever previously associated with cocaine delivery. Reinstatement of
1

drug-seeking has also been observed after re-exposure to the drug (drug priming), drug
cues, or intermittent stressor exposure (Miles et al., 2017; Mantsch et al., 2015; Erb &
Stewart, 1999; Carroll & Comer, 1996). In virtually all models of addiction, drugs have
been shown to simultaneously activate both reward and stress circuits, and while stress
itself may cause relapse, the underlying mechanisms are unclear. However, the
activation of central and peripheral stress responses likely becomes a part of the context
or drug taking. Stress might therefore create a “renewal effect” and cause relapse of
responding when it occurs again after extinction has been conducted in the absence of
stress (see Bouton, 2014; Schepers, 2017; Miles et al., 2017), which has been called the
contextual hypothesis of stress-induced reinstatement. Upon stressor exposure, several
stress response systems are activated, including the hypothalamic pituitary adrenal
(HPA) axis and the sympathetic nervous system (SNS), as well as neural circuits
important for emotional behavior such as fear and anxiety. Brain areas involved in
regulating these physiological and emotional processes may undergo neurochemical
and morphological changes following stressor exposure. These changes may underlie
several mental health disorders (such as post-traumatic stress disorder (PTSD) and
depression; Hammack et al., 2010) including relapse to drug use. Indeed, the activation
of these systems may also be critical to both the maintenance and relapse of addiction.

During a stress-induced reinstatement paradigm, stressor exposure activates the HPA
axis, a central circuit that serves to maintain an organism’s homeostasis by promoting
necessary changes in physiological and behavioral responses to a stimulus. This action
2

is dependent on corticotropin-releasing hormone (CRH) release (Tsigos & Chrousos,
2002). However, CRH activation in extra-hypothalamic brain regions, including the
amygdala and bed nucleus of the stria terminalis (BNST) may mediate some of the
behavioral and physiological symptoms of stressor exposure, including stress-induced
relapse.

The BNST has been linked to anxiety- and stress-responding in both clinical and
laboratory settings (Avery et al., 2016; Walker et al., 2003). Hence, the structure has
been implicated in numerous neurochemical, morphological and physiological
alterations after stressor exposure (Dumont et al., 2008) that enhance BNST function
and mediate stress-related consequences. A heterogeneous structure, activity in the
BNST may be critical for creating and maintaining these alterations long-term. The
BNST has been subdivided into different sub-regions based on neuronal morphology,
afferent and efferent connections, and neurochemistry (see below; Avery et al., 2016).
Moreover, neurons within the BNST express numerous receptor subtypes that bind
multiple neuropeptides, such as CRH (Ch’ng et al., 2018), neurotensin (Moga et al.,
1985), and enkephalin (Haber et al., 1983), among others. This heterogeneity, and the
neuropeptides present, suggests that the regulation of BNST activity is complex (see
Figure 1.5). Several researchers have implicated the BNST oval nucleus in the
mediation of emotional (i.e. stressful) responses (Daniel & Rannie, 2016). Indeed, the
BNST oval nucleus (BNSTov), in addition to containing its own endogenous CRH,
receives CRH inputs from the central amygdala (CeA; an area responsible for
3

autonomic and behavioral components of emotion), and the basolateral amygdala
(BLA; necessary for eliciting fear response) and parabrachial nucleus (PBn),
hippocampus, and medial prefrontal cortex (mPFC), and also projects toward the
paraventricular nucleus (PVN; in the hypothalamus), limbic structures and brainstem
nuclei that mediate emotional behavior (Crestani et al., 2013). The BNST is thought to
aid communication between limbic system structures and emotional processing
systems, as the structure projects to and receives projections from areas responsible for
both emotional and physiological responses to a stressor, and therefore may be
prominent in mediating stress disorders (i.e. stress induced relapse; Roman et al., 2014;
Hammack & May, 2015). Furthermore, the BNST may not only be activated by stressor
exposure but may undergo physiological alterations as a result of stressor exposure
(Lezak et al., 2014); hence, its neurochemistry and morphology is altered with repeated
exposure to stress. In a study of unpredictable stress in rats, several researchers
observed an increase in BNST volume and behavioral manifestations of stress (i.e.
anxiety-like behavior) after 28 days of chronic stressor exposure (Pego et al., 2008;
McEwen & Chattarji, 2007). However, it is important to note that certain sub-regions of
the BNST may be more receptive to prolonged stressor exposure and have greater
morphological and physiological changes than anatomically similar sub-regions. For
example, our laboratory has observed alterations in pituitary adenylate cyclaseactivating peptide (PACAP) and its cognate receptor, PAC1, mRNA levels in the
anterior dorsolateral BNST (BNSTld), but not the ventral BNST (vBNST), following a
repeated variate stress paradigm in rats (Hammack et al., 2009). Additionally, several
4

research teams have observed increases in CRH following the same stress paradigm in
the BNSTld, but not other regions of the BNST – changes that the researchers linked to
an increase in anxiety-like behavior (Lee & Davis, 1997; Schulkin et al., 1998). Hence,
stressor exposure and activation of the HPA axis may be linked to PACAP and CRH
signaling in the BNST.

In females, circulating PACAP levels are correlated with PTSD symptomology and
anxiety-related disorders (see Ressler et al., 2011). As individuals with anxietyspectrum disorders often have maladaptive responses to stress, it reasons that PACAP
levels will correlate to multiple stress-related disorders, including relapse to drug use.
Indeed, there are high levels of comorbidity between individuals who abuse substances
and those who present signs of anxiety-related disorders. PACAP has been implicated
as a key regulator of signaling in stress-related brain regions (Hammack & May, 2015;
Stroth et al., 2011). A neurotrophic factor, PACAP promotes cell survival of multiple
neuron types, including progenitor cells, dorsal root ganglion cells, cerebellar granule
cells, and peripheral sympathetic neurons (Stroth et al., 2011). Importantly, PACAP has
been shown to increase cell survival in response to stressor exposure (Stroth et al.,
2013). Our laboratory and others have argued that PACAP plays a crucial role in stress
responding (for review, see Hammack et al., 2010; Lezak et al., 2014; Mustafa et al.,
2015; Missig et al., 2014). Hence, PACAP may also play an important role in addiction
processes. Indeed, addiction, or substance abuse, is itself a chronic stressor, and as
noted above, many addiction processes may be regulated by stressor exposure. To
5

further understand the role of stress-related peptides on reinstatement processes, we
investigated whether BNST PACAP was, first, necessary and sufficient for the
behavioral properties of stress-induced reinstatement. Next, we examined the
downstream intracellular mechanisms involved in this reinstatement process. In short,
these investigations were aimed at understanding the molecular and anatomical
substrates underlying the relationship between drug-seeking and stress.

The remainder of this introduction is divided into three main sections: 1) neurobiology
of addiction – reviewing the development, maintenance, and relapse phases of
addiction; 2) BNST and its function in addiction processes; and 3) PACAP signaling in
stress-induced reinstatement. The subsequent chapters are primary research studies in
manuscript form, followed by a comprehensive discussion.

1.2. Neurobiology of “Addiction”

Characterization of Substance Abuse
The new Diagnostic and Statistical Manual of Mental Disorders (DSM)-V establishes
diagnostic criteria for two distinct substance related issues: substance use disorders
(addiction), and substance-induced disorders. Diagnosis of substance use disorders is
based upon a pathological set of behaviors related to the use of a given substance:
impaired control, social impairment, risky use, and pharmacological indicators (i.e.
tolerance, withdrawal). For many, the pharmacological indicators that arise as a result
6

of continued use are key indicators of addiction.

Substance abuse is typically characterized by recurring episodes of relapse following
extended drug-free periods (Koob & Volkow, 2010; Erb, Shaham, & Stewart, 1998).
The debilitating condition represents a state whereby drug seeking, and subsequent selfadministration, dominate the user’s thoughts and behaviors. For some individuals, the
tendency to abuse drugs continues despite detrimental side effects, such as health
problems and lost work productivity (Feit & Taylor, 2015). While some argue that
substance abuse represents a loss of self-control (Charbogne, Kieffer & Befort, 2014),
others view addiction as a maladaptive neural plasticity caused by exposure to drugs of
abuse (Feng & Nestler, 2013), although it is unlikely that these views are mutually
exclusive, as loss of self-control and changes in neural plasticity may complement each
other. Hence, multiple factors contribute to substance abuse, including the disordered
regulation of reward systems, environmental stimuli, and vulnerable genes (Jasinska et
al., 2014; Levran et al., 2014). As mentioned, the tendency of users to relapse severely
hinders the adequate treatment of substance abuse disorders. Understanding the
behavioral and physiological mechanisms of relapse processes in substance abuse
disorders is critical to determine viable targets for relapse prevention.

Development of Addiction
Initial investigations of the neurobiology of addiction focused on acute impacts of
drugs of abuse (i.e. physiological effects of a single injection of cocaine). However,
7

in the past several years, the investigative focus has shifted to observing the effects of
chronic administration on brain changes that could lead to relapse (Koob & Volkow,
2010). Indeed, chronic administration is one of the behavioral phenomenon
characterizing the transition from casual drug use to addiction, as noted within the
DSM criteria: “The substance is often taken in larger amounts over a longer period than
was intended” (American Psychiatric Association, 2013). Hence, research in animal
models has utilized two distinct methods of drug-administration to investigate neural
circuits associated with continued drug use. The first, involving experimenteradministered drug, explores the effects of continued drug presence on neurocircuits
involved in addiction (discussed below). Here, behavioral sensitization to the drug is
typically tested in the form of locomotion: animals who receive drug demonstrate
increased responding on test day in response to stress (Seo et al., 2018) or priming
injections (for example, see Blanco et al., 2015) compared to those who receive control
treatment. The second, involving prolonged access to self-administration of drugs, may
have more face validity to human drug-use, but could reflect a sensitization of reward,
or a reward-deficit state (see Vezina, 2004). Here, extended access to drugs results in
increased drug-taking over time, allowing researchers to study the effects of
reinstatement (Miles et al., 2017), latency to goal time in a runway model for drug
reward (Deroche-Gamonet et al., 2004), animals’ willingness to obtain the drug despite
adverse events (Vanderschuren & Everitt, 2004), and the ability of a drug to support
place preference in a conditioned place preference model. Both the experimentaladministered drug model and the animal self-administration model have helped
8

researchers gain a better understanding of the neurobiological substrates for the
reinforcing (i.e. binge/intoxication), negative affect (i.e. withdrawal), and anticipation
(i.e. craving) stages of addiction.

Reinforcement Stage: Olds & Milner (1954) identified a reward system in the brain
after recognizing that rodents would self-administer electrical stimulation to the ventral
tegmental area (VTA). Importantly, rats would continually lever press in order to
receive a brief electrical pulse into the septal region. Continued research in this area
revealed a role of the medial forebrain bundle in reward processing, particularly when
the reward involved norepinephrine (NE; Stein & Himwich, 1962) or dopamine (DA;
Wise, 1978; Koob & Volkow, 2010) release. Indeed, mesolimbic dopamine is critical
for acute, rewarding effects of drugs of abuse (see Robinson & Berridge, 1993; Schultz,
2007). However, different drugs of abuse may activate specific brain regions: animals
will directly administer opioids and alcohol into the VTA (Gatto et al., 1994; Koob &
Volkow, 2010), psychostimulants into the nucleus accumbens (NAcc), and cocaine into
the frontal cortex (McBride et al., 1999). The CeA also demonstrates a key negativereinforcement function in the acute reinforcing effects of drugs of abuse. Intra-CeA
infusion of dopamine D1 receptor antagonists blocks cocaine self-administration (Caine
et al., 1995), and lesions of the CeA block oral alcohol consumption (Möller et al.,
1997). As the CeA and BNST share similar morphologies, and are in close proximity,
we and others have suggested that the BNST may also contribute to negative
reinforcement of drug taking. Indeed, BNST lesions attenuate drug-seeking, and
9

activation causes reinstatement after periods of extinction.

Finally, as the ventral

pallidum (VP) is a key target of nucleus accumbens and drug reward, blockade of
dopamine and GABA receptors in this region blocks the reinforcing effects of acute
alcohol intake (Rodd et al., 2014). Thus, drugs of abuse appear to activate regions
within the mesolimbic dopamine system, and these regions may be critical to the acute
reinforcing effects of drugs.

Withdrawal Stage: While many brain regions are likely responsible for different aspects
of withdrawal, a critical anatomical substrate may be the extended amygdala – a region
comprised of the CeA, BNST, and the “shell” region of the nucleus accumbens. In a
position to receive information from limbic structures like the hippocampus and greater
amygdala, the extended amygdala seems perfectly situated to integrate stress regions
with hedonic processing systems to produce negative emotional states associated with
discontinued drug use. Also prevalent in withdrawal states are multiple neurochemical
systems that may mediate aversive drug states. For example, CRH activates the HPA
axis after chronic (Koob, 2008), but not acute drug use. Our laboratory and others have
suggested that PACAP may be upstream of CRH in several stress-related regions and
may modulate CRH, and subsequent HPA axis activation (see below). In addition to
CRH, norepinephrine has been shown to be critical to the stress response associated
with drug withdrawal, as antagonists administered to extended amygdala areas block
drug-induced place aversion (see Hand et al., 1988; Delfs et al., 2000).

10

Craving Stage: While “craving” has often been suggested as a reason for relapse in the
clinical realm, the term itself is difficult to define. Some view ‘craving’ as an intense
desire or longing (Kozlowski & Wilkinson, 1987), while others think of craving as a
hypothetical construct that can be neither directly observed nor directly measured
(Peers, 2016). Indeed, craving seems to be a rather subjective state in humans that is
associated with drug dependence. However, animal models of craving, and subsequent
relapse, are often studied in the laboratory, as discussed in detail below. Here, cue- and
stress-induced relapse lend some insight to the neuroanatomical and neurochemical
mechanisms that may underlie craving and relapse processes. McFarland & Kalivas
(2001) suggested that drug-induced reinstatement is localized to the nucleus accumbens
and ventral pallidum and mediated by glutamate, whereas renewal processes (i.e.
returned drug seeking in the presence of a contextual cue) may be mediated by the
amygdala (Koob & Volkow, 2016; Everitt & Wolf, 2002; Weiss et al., 2001). Finally,
stress-induced reinstatement may occur during a period of craving and appears to
depend on CRH, PACAP, and norepinephrine in the BNST and amygdala (Miles et al.,
2017; Shaham et al., 2003; Shalev et al., 2002). Notably, the BNST receives projections
from the ventral NE bundle, a cluster of neurons originating from the locus coeruleus
(LC) and lateral tegmental nuclei. Projections from the lateral tegmental nuclei
specifically target the BNST, CeA, hypothalamus, and septum (Aston-Jones, et al.,
1999; Aston-Jones et al., 1997; Delfs et al., 1998) and are activated most prominently
by stressor exposure. The NE bundle, which projects to the BNST and CeA, has been
implicated in the stress responses associated with CRH activation (Delfs et al., 1998).
11

Both

extrahypothalamic

sub-structures

contain

dense

populations

of

CRH-

immunoreactive cells (Shaham, Erb & Stewart, 2000). Furthermore, stressors have been
shown to increase CRH mRNA in CeA (Hammack et al., 2009; Keifer et al., 2015).
The role of the BNST (and not the amygdala) is further supported by prior studies of
CRH administration in the BNST and CeA of animals allowed to lever press for
cocaine (Erb & Stewart, 1999), suggesting the BNST is a critical structure mediating
the effects of stress-induced reinstatement after drug self-administration.

1.3. BNST in Addiction Processes
The BNST is a limbic structure of the extended amygdala that has been widely
implicated in mediating behavioral responses to anxiety and stressor exposure (Choi et
al., 2008; Walker et al., 2003). In particular, the BNST has been specifically implicated
in mediating many PACAP-related stress effects (Hammack et al., 2009; 2010; Lezak et
al., 2014; Roman et al., 2014; Ressler et al., 2011; Vaudry et al., 2002; Stroth et al.,
2011). Anatomically, the BNST is located ventral to the septum, expands both above and
below the anterior commissure, and is anterior to the hypothalamus (Dong et al., 2001); it
is often divided into anterior and posterior regions by fibers of the stria terminalis (Ju &
Swanson, 1989). The anterior region of the BNST can be further divided into wellaccepted sub-nuclei including the anterolateral, anteromedial, oval, dorsomedial, and
magnocellular regions (Dong et al., 2001), among others. The posterior, in contrast, is
sub-divided into only three sub-nuclei: the principal, transverse, and interfascicular. Both
anterior and posterior regions of the BNST

have
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distinct

efferent

and

afferent

projections to other regions within the BNST, and to surrounding brain structures. While
sub-regions of the BNST may differentially regulate stress responding, the anterolateral
division has been largely connected to the behavioral consequences of stressor exposure
(Choi et al., 2007).

The BNST receives and integrates information from many limbic regions, including the
amygdala, prefrontal cortex, and hippocampus. However, the oval nucleus in particular
may be critical in the integration of mood and negative valance leading to heightened
anxiety-like behavioral responding. Indeed, CRH, GABA and PACAP all project from
the oval nucleus to regions further implicated in stress responding, such as the CeA,
VTA, and hypothalamus (Dong et al, 2001). The VTA has also been implicated in reward
and motivation, and BNST projections to the VTA appear to regulate dopaminergic cells
(Georges & Aston-Jones, 2002), further suggesting that the BNST may help integrate
information from stress and reward pathways.

Optogenetic and electrophysiological manipulations of BNST neural circuits
Functional circuit mapping of the BNST is essential for elucidating the distinct
neurocircuitry involved in stress-related behavioral responding. Notably, a study by Kim
et al. (2013) investigated the neural circuits involved in stress- and anxiety-related
behaviors as they relate to reward processes. Photoinhibition of BNST elevated open-arm
time on the EPM (demonstrating increased anxiety), whereas photostimulation of
channelrhodopsin (ChR2) channels in the BNST led to heightened anxiety. Similarly,
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photostimulation of BLA-BNST pathways induced decrements in anxiety, while
inhibition induced heightened anxiety. Furthermore, Jennings et al. (2013) used singleunit recordings to demonstrate that glutamatergic VTA-projecting neurons increase firing
during aversive events, while GABAergic VTA-projecting BNST neurons suppress
firing. Using optogenetic and electrophysiological techniques, Paré and colleagues
showed that the BNST-CeA projecting neurons that target different BNST sub-nuclei
exert inhibitory control over prolonged fear (Gungor et al., 2015; Duvarci et al., 2009).
Lastly, Rainnie et al. (2017) demonstrated that opposing circuits within the BNST
differentially affect cell types related to anxiogenic or anxiolytic behavioral responses.
Indeed, electrophysiological studies show that Type III neurons (characterized by
activation of inwardly rectifying potassium currents; see Hammack et al., 2007) modulate
BNST circuitry related to CRH neuronal activation, a system specifically relevant to
chronic stressor exposure. Continued research in this new area offers a potential route
toward in vivo treatment of stress-related behavioral disorders.

Norepinephrine and Drug Abuse
The noradrenergic system is activated by both acute and chronic stress (for review, see
Morilak et al., 2005; Koob, 1999; Bangasser et al., 2016). Norepinephrine is also active
in response to acute withdrawal states and has been widely cited in relation to addiction
processes (Sinha, 2001; 2007; Blaine & Sinha, 2017; España et al., 2016). Historically, a
central argument discussing whether NE or dopamine is the key mediator of brain reward
states

has

dominated

the

literature.

However,
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the

relationship

between

psychostimulant self-administration and NE has been widely understood and accepted.
Norepinephrine was first implicated in reinstatement paradigms in the mid-1970s when
Davis and colleagues (1975) discovered that blocking NE synthesis attenuates
reinstatement of amphetamines. Since then, accumulating evidence has shown NE
systems to have key role in stress-induced reinstatement. Indeed, administration of NE
receptor (α2AR) agonists decreased NE release by activating inhibitory autoreceptors and
prevented stress-induced reinstatement (Erb et al., 2000). Furthermore, infusion of an
α2AR antagonist, yohimbine, facilitates reinstatement (Lee et al., 2004). Importantly,
these effects seem to involve extended amygdala stress-related areas, as βAR antagonist
blocked stress-induced reinstatement to cocaine seeking when administered to the BNST
or CeA (Leri et al., 2002). Additionally, stress-induced reinstatement of morphine
appears to be NE-dependent: intra-BNST infusion of α2AR agonist, clonidine, blocked
stress-induced reinstatement in a conditioned place paradigm (Wang et al., 2001). The
known role of NE in stress responses could point to the extended amygdala as a critical
component of stress-induced reinstatement. However, the role of BNST CRH and
norepinephrine in processes related to addiction is complex and may depend on the drug
investigated.

Norepinephrine originates from several clusters of neurons - the locus coeruleus and the
lateral tegmental nuclei (NTS) – to project to multiple brain areas via the dorsal and
ventral noradrenergic bundles (Kvetnansky et al., 2009). Notably, CeA is a major source
of CRH afferents to the LC that modulates noradrenergic activity, and NE afferent
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projections directly innervate CRH-containing CeA neurons (Kravets et al., 2015).
Indeed, the lateral bundle provides extended amygdala regions with norepinephrine
critical for stress-induced reinstatement of drug seeking. Shaham et al. (2000) showed
that lesions to this area decreased footshock-induced reinstatement and conditioned place
preference. Furthermore, reinstatement has been induced (and subsequently diminished
by CRH receptor antagonist D-Phe CRH) by ventricular infusions of norepinephrine
(Brown et al., 2009). Hence, CRH is likely downstream from stress-activated
norepinephrine and integration may occur in the BNST.

The BNST in negative reinforcement processes
Addictive behaviors may be maintained through a system of negative reinforcement (see
Koob & Volkow, 2010; 2016). Indeed, an escape from anxiety and dysphoria common
during drug withdrawal may lead to continued drug use. The BNST plays an important
role in the withdrawal stage of addiction (Silberman et al., 2013; Wang et al., 2006),
although it has also been shown to be involved in anxiogenic effects of cocaine selfadministration (Su et al., 2014), and enhanced startle responses throughout intoxication
and craving phases (Logrip et al., 2011). In humans, only a small amount of studies have
investigated the role of BNST in addiction-related processes. However, rodent studies
increasingly show that both anxiety- and addiction-related processes may be mediated by
therapeutic drugs that target the BNST (Walker et al., 2009; Su et al., 2014; Glangetas et
al., 2013).
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Anxiety-like Responses in Drug Abuse
Several lines of research have identified a between-system response to acute withdrawal
from drugs of abuse: anxiety-like responses become prevalent in rodent models of
cocaine withdrawal, such that open arm time in an elevated plus maze decreases
(indicative of anxiety-like behavior), a finding that has been reversed by CRH antagonists
(Koob & Volkow, 2016). This effect, and others, is seen across drugs, and can often be
reversed by administration of a CRH antagonist (Koob, 2008; Funk et al., 2006; Tucci et
al., 2003; George et al., 2007). Importantly, these anxiety-like responses may also be
associated with a decrease in dopaminergic activity in areas associated with the stress
response, such as regions within the extended amygdala.

Corticotropin Releasing Hormone (CRH)
As mentioned above, CRH appears to be a critical regulator of stress responses, as
administration of CRH produces the same physiological and behavioral effects as stressor
exposure. In a clinical setting, patients exhibiting symptoms of major depressive disorder
(MDD), PTSD, and suicidal thoughts (Ressler et al., 2011; Arato et al., 1989; Baker et
al., 1999; Nemeroff et al., 1991) have higher levels of CRH in their system than healthy
counterparts. Depressed individuals also have heightened levels of CRH mRNA in
extended amygdala areas (Merali et al., 2006). Using animal models, Dunn & colleagues
have done numerous studies showing that central CRH administration produces
physiological effects associated with stressor exposure: increased heart rate (Dunn &
Berridge, 1987), increased anhedonia and

anorexic-like behaviors (Dunn & File,
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1987), low sex drive (Dunn & Berridge, 1990), and reduced social interaction (Dunn &
File, 1987).

Two CRH receptors mediate CRH activity: CRH-R1 and CRH-R2. As CRH-R1
antagonists can block the effects of stressor exposure, it is thought that stress effects are
mediated by CRH-R1 (Binder & Nemeroff, 2010). In support of this, CRH-R1 knockout
mice exhibit decreased anxiety-like behavior (Timpl et al., 1998), implicating an
important role of CRH receptors in stress- and anxiety-like behaviors. In the clinical
realm, it is interesting to note that CRH antagonists have been developed to treat stressrelated illnesses, but have been widely unsuccessful (Zorrilla & Koob, 2010). Hence,
CRH receptor activation may be sufficient but not critical for stress responses.

Many studies have investigated the neural circuits underlying stress-induced
reinstatement (Kalivas & Volkow, 2016). For example, Erb & Stewart (1999) have
implicated activation of CRH in stress-induced relapse. Additionally, Shaham &
colleagues (1997) demonstrated that an acute intracerebroventricular (ICV) injection of
CRH mimicked stressor exposure and caused reinstatement, whereas the ICV injection of
a CRH antagonist, α-helical CRH, blocked stress-induced reinstatement in heroin-trained
rats. Furthermore, in a follow-up study done in cocaine-trained rats, Shaham et al. (1998)
showed that CRH receptor antagonists (D-Phe CRH and CP-154.526, respectively) also
attenuated reinstatement to drug seeking. When tested in drug-primed animals, these
manipulations had no effect, indicating an important role of CRH specifically in the
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stress-induced reinstatement paradigm. Initially, the sites of this CRH action were
unclear; however, subsequent studies implicated the BNST as a critical site for stressinduced reinstatement of drug- seeking behavior.

1.4. Pituitary Adenylate Cyclase Activating Peptide (PACAP)
First identified from ovine hypothalamus because of its ability to stimulate cyclic
adenosine monophosphate (cAMP; Miyata et al., 1989) production in pituitary cells,
PACAP has since been implicated in many other areas, including brain, vascular tissues,
and endocrine and immune responses. Indeed, PACAP has been implicated as a key
regulator of signaling in stress-related brain regions (Hammack & May, 2015; Stroth et
al., 2011). A neurotrophic factor, PACAP promotes cell survival of multiple neuron
types, including progenitor cells, dorsal root ganglion cells, cerebellar granule cells, and
peripheral sympathetic neurons (Stroth et al., 2011). Importantly, PACAP has been
shown to increase cell survival in response to stressor exposure (Stroth et al., 2013). The
peptide belongs to the vasoactive intestinal peptide (VIP) – secretin – growth-hormone
releasing hormone (GHRH) – glycagon family and shares multiple characteristics with
peptide VIP (68% amino acid homology; Miyata et al., 1989, 1990). PACAP cDNA
contains codes for a 176-amino-acid protein, which is cleaved into either a 38-amino-acid
or 27-amino-acid form; PACAP38 predominates over PACAP27 in the nervous system
(Vaudry et al., 2009). PACAP-ergic fibers innervate multiple stress-related regions, and
large populations of these fibers are found in the hypothalamus, amygdala, and BNST.
Indeed, the highly conserved nature of

PACAP suggests that it may play a critical
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role in survival. This is supported by the activation of both the HPA axis and the SNS by
systemic and environmental stressors: researchers have postulated that PACAP regulates
stress hormone synthesis in a chronic-stress paradigm (Stroth et al., 2011). PACAP binds
to multiple receptor subtypes: PAC1 (exclusively binds PACAP), VPAC1, and VPAC2
(both of which bind PACAP and VIP; for reference, see May et al., 2010). By binding to
these receptors, PACAP can have various effects on intracellular mechanisms (such as
membrane depolarization and neurotransmitter release; see Figure 1.5 & discussion of
signaling pathways below; Harmar et al., 2012), including neurotrophic and
neurotransmitter-like effects. Furthermore, alternative splicing of the PAC1 receptor
allows even greater signaling diversity: short and long N-terminal extracellular regions
result in differing isoforms that can affect the ability of PAC1 to bind to specific ligands.
Splicing variations can also affect the presence of base-pair cassettes “hip” and “hop,”
further varying the ability of ligand-binding specificity.

PACAP & PAC1 receptors in emotional behaviors
Our laboratory and others have argued that PACAP plays a crucial role in stress
responding (for review, see Hammack et al., 2009; 2010; Lezak et al., 2014; Mustafa et
al., 2015; Missig et al., 2014). Hence, PACAP may also play an important role in
addiction processes. Indeed, addiction, or substance abuse, is itself a chronic stressor, and
as noted above, many addiction processes may be regulated by stressor exposure. PACAP
and PAC1 receptors are highly expressed in areas that project to the HPA axis, and
several studies have demonstrated the

importance of PACAP in HPA signaling
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(Stroth et al., 2011). Furthermore, Stroth and colleagues (2011) demonstrated an increase
in CRH transcription in response to PACAP in hypothalamic cells, and ICV
administration of PACAP increased CRH mRNA in the PVN (Hashimoto et al., 2011).
Finally, PACAP null mice have exhibited impaired long-term HPA axis activation in
response to chronic stressors, an idea that supports the importance of PACAPs role in
HPA axis regulation during a stressful situation (Vaudry et al., 2005; Hammack et al.,
2010). Interestingly, mice deficient in PACAP, when exposed to ethanol, demonstrated
higher tendency to seek the substance than control mice (Tanaka et al., 2010).

Our laboratory has demonstrated that an intra-BNST infusion of PACAP mimics
behavioral and physiological responses to stressor exposure (see Hammack et al., 2009;
2010; Miles et al., 2017). For example, when exposed to a seven-day chronic variate
stress paradigm, rats exhibit anxiety- and anorexic-like behaviors that correspond with a
significant increase in PACAP and PAC1 receptors in the BNST. Bilateral intra-BNST
infusion of PACAP on its own was sufficient to cause the same stress-related behaviors,
including anorexic- and anxiety-like behaviors (Kocho-Schellenberg et al., 2014; Lezak
et al., 2014; Roman et al., 2014). Indeed, PACAP infusions can mimic chronic stressrelated responses by increasing startle, anxiety-like behavior on the elevated plus maze
(i.e. rodents spend more time in the closed arm, indicative of anxiety), decreasing weight
gain and feeding behaviors, and elevating circulating corticosterone levels (Hammack et
al., 2009; Roman et al., 2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014; King
et al., 2017). Additionally, the bilateral intra-BNST infusion of a PAC1 receptor
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antagonist reduced the stress-induced consequences of repeated variate stress, suggesting
that PACAP in the BNST is necessary for the stress responses observed (Roman et al.,
2014). Combined, these data implicate PACAP as an important regulator of stress-related
pathologies (Hammack et al., 2012). Finally, there is some evidence linking PACAP to
different disease states: in humans, PACAP and PAC1 levels are associated with PTSD
and other stress-related disorders in women (Ressler et al., 2011; Hashimoto et al., 2011;
Hashimoto et al., 2016), further implicating PACAP/PAC1 in stress- and anxiety-related
states.

In many stress-related regions, PACAP-immunoreactive fibers appear more prevalent
than soma, suggesting that PACAP signaling may be involved in long-distance
projections (Hammack et al., 2010) rather than local circuits. Furthermore, the source of
PACAP is still largely unknown: originally isolated from the pituitary gland, the highest
densities of PACAP are in the PVN and brainstem regions (Kozicz et al., 1998).
Recently, researchers have demonstrated that PACAP-immunoreactive fibers synapse in
close proximity to CRH-expressing neurons in the PVN and BNST (Sherwood et al.,
2000; Roman et al., 2014; Missig et al., 2014). Hence, PACAP may regulate
neuroendocrine and behavioral responses to stressor exposure via CRH-dependent
mechanisms. That is, PACAP may be upstream of CRH activation. Indeed,
intracerebroventricular (ICV) administration of PACAP has been shown to increase CRH
mRNA in the PVN and CeA (Dore et al., 2013). Hence, stress-released PACAP may bind
to PAC1 receptors on CRH neurons, inducing the synthesis of CRH and eventually
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leading to increased corticosterone levels (although increased plasma corticosterone
levels itself does not necessarily require CRH receptor activation; Meloni et al., 2016;
Lezak et al., 2014; Norrholm et al., 2005). This idea is further supported by studies done
with PACAP knockout mice: here, corticosterone release is diminished in response to
chronic stressor exposure (Stroth & Eiden, 2010), open field exposure (Tsukiyama et al.,
2011) and social defeat stress (Lehmann et al., 2013), but not physical stressors like cold
exposure. Additionally, Roman et al. (2014) showed that PACAP receptor antagonism
via BNST PACAP6-38 administration during a chronic variate stress paradigm reduces
corticosterone release. (While the PACAP6-38 antagonist has been used in multiple
behavioral pharmacology studies in our lab and others, it blocks both the PAC1 and
VPAC2 receptors, so direct effects of PAC1 activity are unknown). Finally, ICV
administration of PACAP reduces sensitivity to reward in sucrose preference and
intracranial self-stimulation (ICSS) tasks (Dore et al., 2013; Seiglie et al., 2015), both
effects that are blocked by CRH antagonists. Hence, PACAP signaling may mediate the
activation of the HPA axis in ways both associated to and disconnected from CRH
receptor activation.

PACAP & PAC1 receptors in addiction-releated behaviors
Recent experiments (Miles et al., 2017) were designed to examine the relationship
between PACAP38, a polypeptide that has been shown to drive BNST CRH, and its
receptor antagonist, PACAP6-38, in stress-induced reinstatement to drug-seeking. We
found that an infusion of PACAP into the

BNST
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was

sufficient

to

reinstate

previously-extinguished cocaine seeking behavior (Figure 1.1). Furthermore, infusion of
PAC1 receptor antagonist, PACAP6-38, immediately before stressor exposure, attenuated
reinstatement to drug seeking when paired with a stressor (Figure 1.2). In an experiment
designed to determine whether 10 days of cocaine self-administration training elevated
BNST PACAP transcripts, similar to what we have previously reported with chronic
stressor exposure (Hammack et al., 2009), we found a five-fold increase in PACAP
mRNA transcript levels in the dorsal aspect of the anteriolateral BNST (dBNST) in
cocaine-responding animals compared to cocaine non-responding animals (Figure 1.3).
Importantly, this increase in PACAP expression appears to be a result of chronic (10d)
cocaine self-administration, as acute cocaine expression (1d) did not alter PACAP
expression compared with control (Figure 1.4). There were no changes in PAC1 or
VPAC2 receptor expression in the same samples, and no difference in transcript levels
following extinction training, indicating that BNST PACAP transcripts likely return to
control level after extinction of the cocaine-seeking behavior (Figure 1.3). Additionally,
while Miles et al. (2017) showed that 10 days of cocaine self-administration significantly
elevated BNST PACAP transcript levels, PAC1, CRH, VIP, VPAC1, and VPAC2
transcript levels, when analyzed, were unchanged. BNST PACAP transcript levels were
not elevated by the reinstatement footshock treatment; however, it is possible that
footshock may lead to peptide release that is not reflected in changes in mRNA. Our
laboratory has previously demonstrated a change in both PACAP transcript and PACAP
immunostaining in the dorsal aspect of the anterolateral BNST following chronic stress,
but changes in protein following chronic cocaine exposure remain unknown.
24

Consistent with a role for active PACAP during reinstatement testing, infusion of
PAC1/VPAC2 receptor antagonist, PACAP6-38, immediately before footshock exposure
prevented the footshock from reinstating extinguished cocaine seeking, thus suggesting
that BNST PAC1/VPAC2 receptor activation is necessary for stress-induced
reinstatement of the response. These dissertation experiments (discussed in detail below)
were designed to examine whether this activation is, indeed, necessary.

PAC1 signaling through extracellular signaling related kinase (ERK) activation
As mentioned above, the mechanism of action underlying PACAP signaling can occur
through three G-protein coupled receptors: PAC1, VPAC1 or VPAC2. Activation of
these receptors has been shown to initiate signaling cascades that can phosphorylate
extracellular signal-related kinase (ERK) proteins that go on to influence multiple
intracellular events (see Figure 1.5; Chang & Karin, 2001). Given the complexity of the
intracellular signaling pathways downstream of PAC1 receptor activation, it is possible
that several signaling pathways lead to pERK activation. Our lab and others have shown
that pERK activation requires endosomal signaling in CeA (May et al., 2010; May &
Parsons, 2017; Missig et al., 2017). Indeed, pretreatment of a PAC1 receptor cell line
with PACAP6-38 (antagonist) blocked PAC1-EGFP receptor internalization typically
stimulated by PACAP. ERK activation here was also diminished, implicating endogenous
CeA PAC1 endosomal ERK signaling in a nociception pathway. Behaviorally, Missig et
al. (2017) showed that a reduction in

thermal latency to CeA-infused PACAP
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could be prevented if tested after administration of MEK inhibitor PD98059 or clathrindependent endocytosis inhibitor Pitstop2. That is, inhibition of clathrin-mediated
endocytosis by Pitstop2 reduced PACAP-induced hypersensitivity on Hargreaves test,
suggesting that PAC1 receptor internalization and subsequent downstream ERK signaling
can modulate nociception responses in the CeA. It is possible that the same signaling
pathways mediate the reinstatement of cocaine seeking behavior following BNST
PACAP (or maxadilan) infusion, or footshock stress. In this set of experiments, we tested
the ability of clathrin-mediated endocytosis inhibitor Pitstop2 to prevent footshockinduced reinstatement following cocaine self-administration and extinction.

Recent work in a model of chronic neuropathic pain demonstrated that PACAP and
phosphorylated ERK (pERK) immunoreactivity was preferentially heightened in the CeA
following a chronic constriction injury (CCI; Missig et al., 2017). In this paradigm, ERK
activation may be a central means of nociceptive signaling, and MEK inhibition to
attenuate CeA PACAP-stimulated pERK in the presence of a blockade of PACAPinduced behavioral tests demonstrated that PACAP/PAC1 receptor mediated ERK
signaling is a requisite for CeA nociceptive hypersensitivity responses in a CCI model
(Missig et al., 2017). In addition, CCI induced a robust increase in anterolateral BNST
pERK cells that were in close proximity to glutamatergic PACAP fibers (Missig et al.,
2017). Furthermore, activation of the ERK transcriptional pathway leads to cocaineinduced behavioral plasticity (Girault et al., 2007), and acute cocaine is known to
increase pERK levels within mouse striatum and NAcc (Janes et al., 2009), while a
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challenge dose increases pERK in rats that had previously experienced cocaine (Yoon et
al., 2007). Hence, pERK may be sensitized prior to this cocaine re-exposure. In this set of
experiments, we sought to identify specific signaling events that likely mediated
PACAP/PAC1-induced increases in BNST pERK, and subsequent relapse, during a
stress-induced reinstatement paradigm. Missig et al. (2017) demonstrated that PACAP38
infusion into the CeA, similar in both structure and function to the BNST, increased
pERK expression. This expression was diminished by the presence of clathrin-mediated
endocytosis inhibitor, Pitstop2, and

mitogen-activated protein kinase enzyme

(MEK)/ERK inhibitor, PD98059. To establish whether BNST PACAP signaling via ERK
can evoke stress-induced reinstatement, the two inhibitors were utilized in this set of
experiments to determine whether their presence abolished footshock/PAC1-stimulated
response to suggest that ERK activation is a critical component of PACAP/PAC1
receptor signaling. Finally, we sought to determine the prevalence of pERK cells
immediately after a stress-induced reinstatement paradigm in which rats receive either
footshock or no-footshock paired with an intra-BNST infusion of PACAP6-38 or vehicle
solution. If pERK expression is mediated by PAC1, the presence of an intra-BNST
antagonist (PACAP6-38) during stressor exposure (i.e. footshock) should prevent the
presence of pERK in an immunohistochemistry analysis. In contrast, animals who receive
the vehicle solution paired with a footshock after cocaine exposure should have “normal”
levels of pERK following stressor exposure, as PACAP-bound PAC1 receptors should
facilitate an intracellular cascade responsible for pERK expression.
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1.5 Summary
Central to the treatment of drug addiction is understanding the cellular mechanisms by
which relapse episodes occur. Prior and current data suggest the activation of BNST
PACAP systems is an important event underlying stress-induced reinstatement to drug
seeking in rodents. Hence, these dissertation experiments aimed to clarify the intracellular mechanisms by which PAC1 receptor activation by PACAP mediates stressinduced reinstatement. The results of these studies are presented in manuscript form in
the following chapters.

While stressor exposure has been linked to human relapse, neuronal mechanisms that
underlie these events are largely unclear. In the laboratory, we have seen the BNST as a
key regulator of reinstatement to drug seeking behavior and suggest that the release of
PACAP in this region mediates changes in emotional responding following stressor
exposure. A growing literature has discussed PACAPs important role in the modulation
of stress and anxiety. The present studies were designed to help further the understanding
of PACAPs role in stress-induced reinstatement. Data from these experiments will help
elucidate PACAPs role in activation of the HPA axis and how stressor exposure triggers
relapse behaviors after a period of abstinence.

These experiments expand upon recent research I conducted examining PACAPs role in
stress-induced reinstatement to drug-seeking behavior (Miles et al., 2017) and, together,
may point to the BNST as an important target in the treatment of drug relapse. Continued
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research of mechanisms that underlie stress-induced reinstatement after a period of
abstinence may lead to the development of viable treatments for relapse prevention.
However, a better understanding of the intracellular mechanisms involved in relapse
processes will be critical to determine how best to target returned drug-seeking.
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1.6 Figures

Figure 1.1. Intra-BNST PACAP38 causes reinstatement of extinguished cocaine
seeking. (A) Self-administration training. Animals in both the PACAP38 and Vehicle
groups received the same amount of cocaine during acquisition (inset). (B) Extinction
training. Extinction sessions occurred during the 20 days after self-administration
training. (C) PACAP38 infusion causes significant reinstatement on the active lever
during test for reinstatement compared with the last day of extinction (1 day before test).
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Figure 1.2. Intra-BNST PACAP antagonist (PACAP6-38) attenuates stress-induced
reinstatement in rats.
(A) Self-administration training. Animals in both the footshock/no-footshock and
vehicle/antagonist groups received the same amount of cocaine during acquisition (inset).
(B) Extinction training. (C) To determine whether PACAP receptor activation during
footshock is necessary for stress-induced reinstatement of cocaine-seeking behavior, we
infused the PAC1/VPAC2 receptor antagonist PACAP6-38 into the BNST during the test
phase of the stress-induced reinstatement procedure. Intra-BNST PACAP6-38 attenuates
stress-induced reinstatement when delivered before intermittent footshock. Intra-BNST
delivery of the PACAP antagonist significantly attenuated shock-induced reinstatement.
Only animals that received intra-BNST vehicle treatment before footshock demonstrated
reinstatement of extinguished drug-seeking behavior.
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Figure 1.3. Cocaine self-administration alters endogenous PACAP levels in the
BNST. Adult male rats self-administered cocaine for 10d, and several underwent 20d
extinction training. dBNST was harvested for quantitative PCR analysis after 10d selfadministration, or after self-administration followed by 20d extinction training. (C) 10d
cocaine self-administration increases PACAP in cocaine responders, but not nonresponders. Neither 10d cocaine self-administration nor 20d extinction training altered
(D) PAC1 or (E) VPAC2 receptor transcript in cocaine responders and non-responders in
the BNST.
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Figure 1.4. PACAP transcript levels after acute cocaine self-administration. Acute
cocaine exposure (1d) did not alter PACAP expression compared to control.
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Figure 1.5. Modified schematic of PAC1 receptor signaling cascade. Arrestin
molecules aid in endosome signaling following PAC1 receptor internalization. They then
serve as scaffolds for adaptor proteins and enzymes for extracellular signal-related kinase
(ERK) pathway activation. MEK pathways may also interact with ERK signaling.
Clathrin dependent endocytosis inhibitor (Pitstop2) will serve to inhibit endosomal
signaling. Thus, PAC1-mediated stress-induced reinstatement may be altered. MEK
inhibitor PD98059 serves to block MEK, further downstream of PAC1. Blocking this
stage of the cell signaling cascade prevents stress-induced reinstatement to drug-seeking
in the presence of footshock.
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CHAPTER 2: INTRA-BNST MAXADILAN INFUSION MIMICS STRESSOR
EXPOSURE AND INDUCES REINSTATEMENT OF DRUG-SEEKING
BEHAVIOR

2.1. Introduction
The BNST PACAP receptor subtypes mediating the reinstatement of cocaine-seeking
behavior by stress are unknown. Therefore, Experiment 1 was designed to specifically
test whether PAC1 (rather than VPAC1 or VPAC2) receptor activation mediates stressinduced reinstatement. As mentioned above, our laboratory has produced data
demonstrating that an intra-BNST infusion of PACAP38 (Figure 1.1) mimics stressor
exposure and induces reinstatement to drug-seeking following a period of extinction in
rats who learned to lever-press for cocaine. Furthermore, infusion of PAC1/VPAC2
receptor antagonist, PACAP6-38, immediately before footshock exposure prevented the
footshock from reinstating extinguished cocaine seeking (Figure 1.2), suggesting that
BNST PAC1/VPAC2 receptor activation is necessary for stress-induced reinstatement of
the response. These results are consistent with hypotheses suggesting that stress systems
have a role in the vulnerability to relapse following stressor exposure (Koob & Le Moal,
2008). Hence, BNST PACAP activation may be critical for regulating extinguished drug
seeking following stressor exposure.

PACAP effects can be mediated by three receptor subtypes that bind with different
affinities to PACAP and VIP. PAC1

receptor activation can lead to the
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activation of several intracellular signaling cascades, including adenylate cyclase (AC)
and phospholipase C (PLC), depending on the PAC1 receptor isoform activated. The
resulting activation can subsequently result in heightened membrane depolarization,
neurotransmitter release, and action potential firing (Harmer et al., 2012; Spongier et al.,
1993; Braas & May, 1999). Also activated are pathways important for neurodevelopment
and neuroplasticity following stressor exposure, such as the ERK and phosphoinositide 3kinase (PI-3) pathways. Furthermore, PACAP/PAC1 dysregulation may participate in the
development of physiological disorders, such as anxiety and depression (Hammack &
May, 2015).

Our laboratory has previously reported that chronic stress (but not cocaine selfadministration; Experiment 1 in Miles et al., 2017) upregulates BNST PAC1 receptor
transcripts, but not BNST VPAC1/VPAC2 transcripts (Lezak et al., 2014; Hammack et
al., 2009). Moreover, many of the consequences of stressor exposure can be mimicked by
infusion of the PAC1 receptor agonist maxadilan in the BNST (Roman et al., 2014).
Indeed, PACAP-induced anxiety-like and anorexic responses have been fully
recapitulated with an infusion of maxadilan. A 61-amino acid sand fly salivary gland
peptide, maxadilan is currently the only PAC1 receptor specific ligand identified to date
and demonstrates high efficacy in initiating behavioral responses that match those
produced by PACAP- or stress-induced states. Hence, it is likely that the stress-like
effects of BNST PACAP activation are mediated by PAC1 receptors.
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From these observations, we hypothesized that maxadilan treatment would recapitulate
our previous findings (Experiment 3 in Miles et al., 2017) and mimic stress-induced
reinstatement. Here, we utilized a stress-induced reinstatement paradigm in which
animals were allowed to lever-press for cocaine for 10 days, followed by 20 days
extinction training (where lever presses no longer resulted in drug delivery) and a test day
where animals received vehicle or maxadilan treatment paired with either footshock or no
footshock. Since we propose the PAC1 receptor is responsible for PACAP- and stressmediated reinstatement, we expected to see an increase in active lever (previously
associated with cocaine delivery) responses on test day for animals who received intraBNST maxadilan and previously learned the cocaine lever-press association compared to
animals who received vehicle treatment.

2.2. Materials & Methods
Subjects
Consistent with our work investigating the role of BNST PACAP in stress-related
behavior, adult male Sprague-Dawley rats (n=30) obtained from Charles River
Laboratories (Canada), were individually housed and received water and chow ad
libitum. After delivery, rats were allowed to habituate to their home cage for 1 week
before undergoing surgeries. Rats were maintained on a 12h light/dark cycle (lights on at
0700 h) and all experimentation occurred with lights on (between 0730 and 1130). All
procedures were approved by the institutional animal care and use committee at the
University of Vermont.
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Apparatus
Two sets of four conditioning chambers were used. Each is housed in its own soundattenuation chamber (Model ENV-008-VP; Med Associates; St. Albans, VT). The
chambers measure 30.5 x 24.1 x 21.0 cm (length x width x height). The floor is made of
stainless steel grids (0.48 cm diameter). The sidewalls and ceilings are made of clear
acrylic plastic, whereas the front and rear walls are made of brushed aluminum. A
retractable lever (4.8 cm long and positioned 6.3 cm above the grid floor) is positioned on
the right and left sides of the chamber (the left-hand lever was used as a control (inactive)
lever). A stimulus light is positioned above each lever, and each chamber is illuminated
by a 7.5 incandescent bulb mounted to the ceiling of the sound-attenuation chamber, ~35
cm from the grid floor at the front of the chamber. The operant conditioning chambers are
linked to a computer data collection program (MED PC, Med Associates).

Surgical Procedures
All rats received a jugular vein catheter implantation. Rats were anesthetized using
isoflurane vapor (1.5-4.0%) and all surgical procedures were conducted using aseptic
techniques. Catheters were constructed using methods previously described (Fuchs et al.,
2004) and consisted of external guide cannula with screw-type connectors (Plastics One,
Roanoke, VA), silastic tubing (10 cm; SAI Infusion Technology, Lake Villa, IL), and
prolite polypropylene monofilament mesh (2 cm diameter; Biomedical Structures,
Warwick, RI). The end of the catheter was inserted into the right jugular vein, secured
with suture, and exited on the rat’s back, posterior to the shoulder blades. To maintain
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patency, catheters were flushed once daily for 6 days after surgery with 0.2 ml
heparinized saline. For the duration of the experiment, each animal received 0.1 ml
heparinized saline immediately before and directly after each self-administration session
to ensure catheter patency.

Immediately following the jugular catheterization, animals were implanted with bilateral
cannula (22 gauge, Plastics One, Roanoke, VA) aimed at the BNST as previously
described (Hammack et al., 2009). Cannula were mounted onto stereotaxic arms and
aimed at an angle of 20° just dorsal to the oval BNST (from bregma: AP = -0.1, ML =
+3.8, DV = -5.3). Wire stylettes extending 1 mm past the tip were inserted into each
guide cannula and cemented in place. Animals received subcutaneous injections of
lactated Ringer’s solution and an analgesic (5mg/kg, Metacam, Boehringer Ingelheim,
Vetmedica, St. Joseph, MO) administered once immediately after the dual surgery and
once the following day. Once awake, rats were returned to their home cages for 7-day
post-surgery recovery, during which all rats were observed and weighed daily.

Cocaine Self-Administration (Acquisition)
At 7 days after surgery, all rats were given the opportunity to self-administer cocaine
(cocaine hydrochloride, 3.0mg/ml, obtained from PENRO Specialty Compounding,
Colchester, VT) during daily 1 hr sessions for 10 days according to a fixed ratio 1
schedule of reinforcement. At the start of each session, the catheter was connected to a
swivel via polyethylene 20 tubing that was encased in steel spring lashes (Plastics One).
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After the animals were placed in the chamber, a 2 minute period elapsed before the
stimulus light came on above the active lever (signaling drug availability). Presses on the
active lever resulted in a 0.5s cocaine infusion and a 2s flashing light presentation of the
stimulus light above the active lever (0.5s on/0.5s off).

Extinction
Over the next 20 days, all rats received a single daily session in which levers were
available but had no programmed consequence (i.e. lever presses no longer resulted in
cocaine delivery). These extinction sessions lasted 1 hr.

Reinstatement
On the day following the last extinction session, rats were split into four groups,
counterbalanced for order and time of testing, that received different treatments. Rats
received an infusion into the BNST of PAC1 specific agonist maxadilan (1.0 µg; 0.5
µl/side; gifted from Ethan Lerner, Harvard/Massachusetts General Hospital) to
recapitulate previous findings and confirm the involvement of the PAC1 receptor, or
equivolume 0.05% BSA saline vehicle immediately before the test session (between 0730
and 0930 h) as previously described (Hammack et al., 2009). For all infusions, rats were
lightly restrained with a cloth towel and the stylettes removed and replaced with an
internal cannula, extended 1 mm distally, for infusions at 0.25 µl/minute. Following
infusion, the internal cannula was left in place for 1 minute to allow complete diffusion of
the drug away from the infusion tip. Immediately following bilateral infusion, the rats
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were placed in the operant conditioning chambers and allowed to lever press for 1 hr.

Histology
Rats were anesthetized 1 day after reinstatement testing with Beuthanasia-D (sodium
pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially with 200 ml
saline (0.9%) with 0.1% heparine (Sagent, Schaumburg, IL) followed by 100ml of 10%
formalin solution (Fisher Scientific, Atlanta, GA). Brain tissues were postfixed at 4°C for
24 h in 10% formalin. Fixed tissue was then cut using a cryostat, and sections were
collected at 60 µm thickness. Sections were then dry mounted, stained with cresyl violet
stain, and cover slipped. Cannula placements were visualized using a 4x Nikon Objective
on an Olympus microscope. Only data from correct BNST cannulae placements are
described in the Results.

Data Analysis
Statistical analysis was completed using SPSS Version 21 software (IBM Software,
Armonk, NY) and graphical representations were completed using GraphPad Version 6
(GraphPad Software, San Diego, CA).

2.3. Results
Our previous studies (Miles et al., 2017) have implicated the PAC1 receptor in stressinduced reinstatement to drug-seeking: an intra-BNST infusion of PACAP38 (Figure 1.1)
mimics stressor exposure and induces

reinstatement to drug-seeking following a
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period of extinction. PACAP binds to several PACAP/VIP receptor subtypes, as
discussed above, and prior studies have implicated BNST PAC1 receptor signaling in
stress-related responses (Roman et al., 2014). Infusion of maxadilan, the only PAC1
receptor-specific ligand identified to date, was expected to mimic stressor exposure and
induce reinstatement of active lever press responding in the absence of stressor exposure.

Figure 2.1 illustrates the timeline of Experiment 1. Data from 22 animals were used in the
analyses for the tests for reinstatement, as post-test histological examination of injection
sites for these rats were found to be placed appropriately in the BNST. Three animals
who completed behavioral testing had improperly placed cannula and were excluded
from the analysis; two animals lost skull caps during infusion and were immediately
sacrificed prior to behavioral test; three animals lost skull caps during extinction training
and were not included in any analyses. Figure 2.2 portrays the distribution of cannula
placements in analyzed animals.

Self-Administration Training
Immediately after the last acquisition session, a median split analysis for total lever
presses over 10d was used to separate cocaine responders (M=172, SD=13.3; those who
successfully learned the lever press response and progressively increased responding over
acquisition) from cocaine non-responders (M=35, SD=3.47; those who did not learn the
lever press behavior and received very little drug over acquisition). Cocaine responders
self-administered an average [mean (±SEM)] of 17.2 (± 0.79) infusions of cocaine HCL
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per hour, 0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders
self-administered an average of 3.5 (± 1.02) infusions per hour, 0.75mg/kg/infusion, over
the same 10 d period. The mean (±SEM) number of responses made on the inactive lever
throughout acquisition was uniformly low across responders and non-responders per
session, 1.59 (± 0.68). Furthermore, there was a significant time effect in cocaine
responders (F(1,8)=14.39, p<0.01), but not cocaine non-responders (F(1,8)=1.42, N.S.)
over acquisition, indicating that only cocaine responders learned the lever press response
and increased responding over time. Data is portrayed in Figure 2.3 (A).

Extinction
By the end of extinction (Figure 2.3 (B)), all cocaine responders had reached ≤ 10
responses; cocaine non-responders reached ≤ 5 responses. Inactive lever responses
remained uniformly low throughout extinction. Interestingly, in this experiment (more so
than Experiments 2, 3, & 4; see below), extinction responses between cocaine responders
and non-responders remained significantly different throughout the 20 days of training.
Figure 2.3 (B) shows a distinct difference in active lever responding on the last day of
extinction for cocaine responders vs. non-responders, perhaps indicative of the
reinforcing effects of cocaine administration during acquisition such that cocaine
responders continued to lever press slightly throughout extinction in the hopes of
receiving an infusion. There was a significant effect of time in cocaine responders
(F(1,8)=7.94, p<0.05), but not non-responders, indicating that lever press responses on
the active lever significantly decreased over extinction. The mean (±SEM) number of
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responses made on the active and inactive levers on the last day of extinction and during
the test for reinstatement are shown in Figure. 2.3 (C, D).

Reinstatement
Bilateral intra-BNST infusion of selective PAC1 receptor agonist, maxadilan,
significantly increased active lever responding in the test session in cocaine responders.
Only rats that received maxadilan increased responding on the active lever during the test
for reinstatement. No significant differences in responding were found between animals
infused with BSA vehicle solution. A treatment (maxadilan, vehicle) by session (last day
of extinction, test) ANOVA supported these observations. There was a significant effect
of session (F(1,8)=8.042, p<0.05), and a session by treatment interaction (F(1,8)=7.332,
p<0.05). Importantly, animals in both the maxadilan and vehicle groups received the
same amount of cocaine during acquisition (Figure 2.4), indicating that reinstatement was
elicited by maxadilan infusion rather than total cocaine intake during acquisition. The
post hoc analyses comparing maxadilan and vehicle infusion on total responses on the
active lever in the absence of footshock stress revealed significantly more responding in
the maxadilan condition. Maxadilan did not alter responding on the inactive lever, and
responses on the inactive lever remained uniformly low during testing.

In contrast, maxadilan infusion had no effect on active lever responses on test day in
cocaine non-responders (F(1,8)=0.4298, NS). Hence, maxadilan infusion only increases
active lever press responding (and mimics stress-induced reinstatement) if the animal is
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cocaine experienced, a finding that may be PACAP dependent. This data, and other
experiments in this dissertation, may suggest a permanent change in the PACAP system
(i.e. sensitization) following cocaine exposure.

2.4. Discussion
To facilitate understanding of PACAPs role in the BNST, our prior studies (Miles et al.,
2017) demonstrated that PACAP infusions into the BNST mimicked stress-induced
reinstatement behavioral responses. The effects of PACAP are mediated by both PAC1
and VPAC2 receptors. Here, we showed that stress- and PACAP-elicited BNST
behavioral effects could be recapitulated using maxadilan, implicating specific activation
of the PAC1 receptor in these behavioral responses. Maxadilan was first isolated from the
salivary gland of the sand fly in 1991 and has been widely studied as a vasodilator
peptide (Tatsuno et al., 2001; Lerner et al., 2007). While maxadilan appears biologically
active and has effects at specific binding sites, the peptide itself is not endogenous to
mammals. However, as noted above, maxadilan does bind to PACAP receptors in
mammals despite its lack of amino acid homology with PACAP. Indeed, Moro and
colleagues (1999) showed that maxadilan binds specifically to the PAC1 receptor, as
deletion of 17 amino acids from maxadilan (max.d.4) resulted in a peptide with binding
affinity for PAC1, but no functional activity. The mutated max.d.4 failed to activate
downstream targets of the PAC1 receptor (and was eventually deemed a competitive
antagonist of PAC1 receptors), demonstrating that maxadilan specifically interacts with
PAC1 to stimulate downstream cyclic AMP

production. Furthermore, maxadilan, but
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not VIP, increases the excitability of guinea pig cardiac neurons (Braas et al., 1998;
Hoover et al., 2009).

Prior studies (Miles et al., 2017) demonstrated an increase in PACAP transcript following
10d cocaine self-administration, but no increase in PAC1 transcript. Perhaps the
increased PACAP transcripts represent a decrease in PACAP binding to PAC1 receptors
due to heightened PAC1 receptor internalization: if mature PACAP is prevented from
binding due to PAC1 receptor internalization, but available in the synapse, mRNA
transcripts may not undergo translation to make more peptide (discussed below; May et
al., 2014; Merriam et al., 2013; May & Parsons, 2017). That is, as PAC1 receptors
undergo clathrin-mediated endocytosis, they are no longer available to bind PACAP,
which would explain our finding that PACAP transcript levels are increased following
cocaine self-administration, but PAC1 transcript levels remain unchanged. These studies
in aggregate implicate PACAP and PAC1 receptor involvement in the behavioral
consequences of stress-induced reinstatement to drug-seeking.

Within the BNST, the location of PAC1 receptors mediating stress-induced reinstatement
is unknown. However, prior studies have revealed a cluster of CRH neurons within the
dorsolateral and ventrolateral regions of the BNST with higher concentrations in the oval
nucleus (Silberman et al., 2013) that appear to mediate many effects of drug-related
anxiety and reinstatement (Jennings et al., 2013). Indeed, Erb and colleagues (2001)
suggested a prominent role of CRH projections from the CeA in stress-induced
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reinstatement. But more recent studies have shown that stress activates neurons in the LC
that release norepinephrine and elicit action potentials from CRH neurons within the
BNST (Silberman et al., 2013). Since CRH neurons in the BNST are primarily
GABAergic, actions on these neurons may be involved in anxiety-inducing aspects.
Perhaps PAC1 receptors on CRH neurons within the BNST are responsible for cocaine
“withdrawal” during extinction and subsequent reinstatement to drug-seeking following
stressor exposure.

VIP, a neuropeptide with strong homology with PACAP, has similar biological functions
to PACAP within the central nervous system (CNS). PACAP and VIP both form the
PACAP/VIP receptor family to which PACAP and VIP both bind with different
affinities. Several studies have suggested that VIP may mimic the physiological action of
PACAP but requires large concentrations to show biological effects (Pincus et al., 1990).
In vivo, PACAP could be acting in conjunction with VIP to stimulate receptors
responsible for the behavioral reactions to stressor exposure. Here, if animals had not
reinstated drug-seeking on test day in response to maxadilan infusion, it would have been
feasible that previously reported results depend on the VPAC2 receptor, which also binds
PACAP. However, Miles et al. (2017) showed that chronic cocaine administration did not
alter VIP, VPAC1 or VPAC2 transcript levels in the BNST. This makes logical sense, as
the BNST contains high expression of PAC1 receptors (Kash et al., 2015; Hashimoto et
al., 1996) and little expression of VPAC1 and VPAC2 receptors (Ishihara et al., 1992;
Kash et al., 2015). Hence, PAC1 is the most likely post-synaptic target of BNST PACAP.
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Recently, Ressler and colleagues (Ressler et al., 2011; Dias & Ressler, 2013) showed that
traumatized women had higher levels of blood PACAP than healthy age-matched
controls, which complements studies showing an increase in PACAP and PAC1 mRNA
transcripts in the extended amygdala of adult rodents following a fear conditioning
paradigm. Together, these findings suggest that PACAP may be involved in some of the
symptoms characteristic of women with post-traumatic stress disorder (PTSD; Dias &
Ressler, 2013). Because the PACAP-PAC1 receptor system has been studied for its role
in stress responsiveness (Hammack et al., 2009; Vaudry et al., 2009; Stroth et al., 2011),
the possible convergence between stress and biological components of PTSD should be
further investigated. Furthermore, stressor exposure has been shown to induce relapse in
vulnerable former addicts. Hence, there may be concordance between stressor exposure
(i.e. trauma), drug-use, and subsequent stress-induced relapse that depends on the
extended amygdala PACAP system.
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2.5 Figures

Jugular Catheterization & BNST
Cannulation Surgeries
Post-Op (7 days)

Test for Reinstatement
Cocaine SA (10 days)

Perfusion

Extinction (20 days)

Intra-BNST Infusion of Maxadilan or
Vehicle 15 min prior to behavioral test

Figure 2.1. Timeline for Experiment 1.
Jugular catheterizations and BNST cannulations were performed concurrently in rats for
self-administration and test-day infusions, as shown in the experimental timeline. This
was followed by one week of post-operative recovery, 10d cocaine self-administration
training, 20d extinction training, and a test day. Infusions of maxadilan or vehicle
treatment occurred 15 minutes prior to the animals’ reintroduction to the operant
conditioning chambers on test day. Animals were perfused 1d after test for cannula
verification.

49

0.36

-0.48

0.24

-0.60

0.12
-0.72
0.00

-0.84

-0.12

-0.24

-0.36

Figure 2.2. BNST Cannula Placements.
Cannula placements are depicted above such that enclosed red dots represent a 1mm
extension beyond the tip of the cannula. Rats were included in the analysis if their
placement resided within a portion of the BNST; they were eliminated from analysis if
their cannulae placement fell outside the histological boundary of the BNST, fell within
the lateral ventricles, or if animals did not complete behavioral testing.
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Figure 2.3. Intra-BNST maxadilan infusion induces reinstatement of drug-seeking
in the absence of stressor exposure.
(A) Self-administration training on the active lever during Experiment 1; inactive lever
presses remained uniformly low throughout acquisition. A median split analysis for total
lever presses over 10d was used to separate cocaine responders (M=172, SD=28.89) from
non-responders (M=35, SD=3.47). (B) Extinction training during Experiment 1.
Extinction sessions occurred during the 20 days after self-administration training. (C) To
determine whether PAC1 receptor activation is necessary during reinstatement to drugseeking, we infused the PAC1 specific

receptor agonist maxadilan into the BNST
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during the test phase of the reinstatement procedure. Intra-BNST maxadilan induces
reinstatement on the active lever (previously associated with cocaine delivery) in cocaine
responders, but not cocaine non-responders (D) in the absence of footshock stress. Only
animals that received intra-BNST maxadilan treatment demonstrated reinstatement of
extinguished drug-seeking behavior. Group Responders-Vehicle, n=6; RespondersMaxadilan, n=6 Non-Responders-Vehicle, n=5; Non-Responders-Maxadilan, n=5. Data
represent mean lever presses ± SEM.
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Figure 2.4. Total cocaine infusions over 10d acquisition.
Animals in both the maxadilan (M=175.5 SD=38.12) and vehicle (M=159.8, SD=58.36)
groups received the same amount of cocaine during acquisition, indicating that
reinstatement was elicited by maxadilan infusion rather than total cocaine intake during
acquisition.
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CHAPTER 3: COCAINE EXPERIENCE POTENTIATES SHOCK-INDUCED
pERK VIA PAC1 RECEPTOR MECHANISM

3.1. Introduction
Our laboratory has previously reported that PAC1 receptor activation leads to
intracellular signaling cascades that result in increased pERK expression. Furthermore,
Experiment 1 was designed to determine whether PAC1 receptor activation could
recapitulate the effects of stress on cocaine reinstatement. Theoretically, with the
exposure of a stressor (i.e. footshock), PACAP release should bind to the PAC1 receptor
and activate intracellular signaling cascades that, in addition to opening different ion
channels, increases pERK expression. Furthermore, it is well known that cocaine
activates stress response systems in addition to reward systems. Hence, it is feasible that
cocaine self-administration alone activates the PAC1 signaling cascade and subsequently
increases pERK expression.

The pharmacology of PACAP in the BNST is complex, but Walker et al. (2014) recently
showed that both splice variants of PACAP (38 vs. 27), but not VIP, activate cellular
cAMP production. Furthermore, in an experiment examining the effects of PACAP
protection against high-alcohol and high-nicotine toxicity, Manavalan and colleagues
(2017) showed that PACAP blocks toxicity induced by high alcohol and nicotine, but
these effects of PACAP were blocked after

PACAP6-38
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administration.

Our

laboratory has previously demonstrated a change in both PACAP transcript and PACAP
immunostaining in the dorsal aspect of the anterolateral BNST following chronic stress
(Hammack et al., 2009). Consistent with a role for active PACAP during reinstatement
testing, infusion of PAC1/VPAC2 receptor antagonist, PACAP6-38, immediately before
footshock exposure prevented the footshock from reinstating extinguished cocaine
seeking, thus suggesting that BNST PAC1/VPAC2 receptor activation is necessary for
stress-induced reinstatement of the response (Miles et al., 2017). Here, we proposed that
stressor exposure during a test for reinstatement induces ERK phosphorylation and,
therefore, increases pERK levels in the BNST. Our prior results are consistent with
hypotheses suggesting that stress systems have a role in the vulnerability to relapse
following stressor exposure (Koob & Le Moal, 2008), and prior work has suggested that
BNST PACAP activation may be critical for regulating extinguished drug seeking
following stressor exposure.

3.2. Materials & Methods
Subjects, Apparatus, & Surgical Procedures
The subjects were 26 naïve male Sprague Dawley rats of the same age and from the same
vendor as those in Experiments 1. They were also maintained under the same conditions
and utilized the same apparatus as that used in Experiment 1. All animals received both
the jugular catheterization and BNST cannulation as described above.

Cocaine Self-Administration (Acquisition)
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Seven days post-surgery, animals were allowed to lever press for cocaine (cocaine
hydrochloride, 3.0mg/ml, obtained from the same vendor as in Experiment 1) during
daily 1 h sessions for 10 days according to a fixed ratio schedule of reinforcement.
Animals received the same conditions inside the operant chambers as animals in
Experiment 1.

Extinction
Extinction sessions proceeded as described in Experiment 1.

Reinstatement
On the day following the last day of extinction, rats were split into four groups,
counterbalanced for order and time of testing, that received different treatments. Rats
received an infusion into the BNST of the PAC1 receptor antagonist PACAP6-38 (1µg)
paired with footshock or no footshock to observe downstream pERK activation, or
equivolume 0.05% BSA saline vehicle immediately before test. Directly following
bilateral infusion, animals were placed into the operant conditioning chambers and
allowed to lever press (while active and inactive lever presses were recorded; no cocaine
was delivered to the animals during test day). Animals were broken into groups based on
three factors: Cocaine responders vs. non-responders, Footshock vs. No Footshock, and
Antagonist vs. Vehicle treatment. Hence, the groups were as follows: Responders-ShockPACAP6-38, n=4; Responders-NoShock-PACAP6-38, n=4; Responders-Shock-Vehicle,
n=4; Responders-NoShock-Vehicle, n=4; NonResponders-Shock-PACAP6-38, n=3;
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NonResponders-NoShock-PACAP6-38,

n=3;

NonResponders-Shock-Vehicle,

n=2;

NonResponders-NoShock-Vehicle, n=2.

Histological and Immunohistochemistry Procedures
One hour after the test session ended, rats were deeply anesthetized with Beuthanasia-D
(sodium pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially with
saline, followed by a 4% paraformaldehyde solution before tissue dissection. All tissues
were post-fixed overnight in 4% paraformaldehyde, rinsed in phosphate buffer saline, and
equilibrated in 30% sucrose before cryosections (30 µm) were floated in PBS for
staining. All sections were then permeabilized with 0.3% Titron X-100 and blocked with
1% BSA. Immunocytochemical staining for pERK (1:1000, Phospho-p44/42 MAPK
(Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology, Danvers, MA)
occurred after extensive buffer rinses, and was followed by treatment with a speciesspecifi AlexaFluor 488 secondary antibody (1:500, 4hr; ab150077; Abcam).

Image Analysis
Micrographs were acquired with a 10x objective using an Olympus fluorescence
microscope (Nikon

Instruments, Melville, NY) and StereoInvestigator (MBF

Biosciences, Williston, VT) software. BNST fields in the different brains were identified
using the anterior commissure, lateral ventricles, and outer field of the caudate putament
as reference points and landmarks. All images for this experiment were acquired under
identical settings and parameters. For enumeration of pERK cells in prescribed areas, a
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semi-autonomous cell counting method was utilized. All data represents mean values ±
SEM.

Data Analysis
All statistical tests were performed as described in previous experiments.

3.3. Results
Figure 3.1 displays the timeline of events for Experiment 2. Data from 26 animals were
used in the analysis for the tests for reinstatement, as histological examination of
injection sites for these rats were found to be placed appropriately in the BNST. Figure
3.2 portrays the distribution of cannula placements in analyzed animals.

Self-Administration Training
The results of acquisition, extinction, and testing are shown in Figure 3.3. As in
Experiment 1, a median split analysis for total lever presses over the 10d of acquisition
was used to separate cocaine responders (M=95.14, SD=2.98), from non-responders
(M=37, SD=0.68). Both groups performed uniformly low on the inactive lever. Cocaine
responders self-administered an average of 9.5 (±0.94) infusions of cocaine HCL per
hour, 0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders selfadministered an average of 3.7 (±0.21) infusions per hour, 0.75mg/kg/infusion, over the
same 10d period. The mean number of responses made on the inactive lever throughout
acquisition was uniformly low across

responders
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and

non-responders

per

session, 1.24 (±0.24).

Extinction
By the end of extinction, all rats had reached ≤ 5 responses; inactive lever responses
remained uniformly low throughout extinction. The mean number of responses made on
the active and inactive levers on the last day of extinction and during the test for
reinstatement are show in Figure 3.3 (C, D).

Reinstatement
Bilateral intra-BNST infusion of PAC1 receptor antagonist PACAP6-38 significantly
attenuated active lever responding in the test session of cocaine responders after stressor
exposure. Only animals that received vehicle solution paired with footshock increased
responding on the active lever during test for reinstatement (stress-induced reinstatement
that has been well documented by our laboratory and others). No significant differences
in responding were found between animals infused with BSA vehicle solution. A
treatment (PACAP6-38, vehicle) by session (last day of extinction, test) ANOVA
supported these observations. In cocaine responders, there was a significant effect of
session (F(1,9)=80.37, p<0.0001), and significant interactions between session and shock
(F(1,9)=2.616, p<0.05), and session and infusion treatment (F(1,9)=7.11, p<0.01).
Finally, there was a significant session by shock by infusion treatment interaction
(F(1,9)=5.50), p<0.01), consistent with the fact that only animals that received the
footshock and vehicle infusion demonstrated stress-induced reinstatement. Cocaine
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responders in both vehicle and antagonist group received the same amount of cocaine
during acquisition (Figure 3.4), indicating that reinstatement was elicited by footshock
exposure rather than total cocaine intake during acquisition. Hence, these results
completely recapitulate previous findings that demonstrate PACAP6-38 blocks
reinstatement of extinguished cocaine seeking when exposed to footshock stress (see
Miles et al., 2017, Experiment 2). The post hoc analysis comparing PACAP6-38 and
vehicle infusion on total responses on the active lever after footshock exposure revealed
significantly less responding in the PACAP6-38 condition (p<0.01). Additionally, the
number of responses on the active lever in the no-footshock condition after injections of
PACAP6-38 did not differ from lever press activity after vehicle infusion. PACAP6-38
did not alter responding on the inactive lever, and responses remained uniformly low
during testing.

There was no significant difference in any condition (footshock vs. no footshock;
PACAP6-38 vs. vehicle) in cocaine non-responders on test day compared to the last day
of extinction. Hence, PACAP6-38 appears only to block stress-induced reinstatement if
the animal is cocaine experienced.

BNST ERK Signaling in Stress-Induced Reinstatement
This experiment sought to completely block the PAC1 receptor (using PAC1 antagonist
PACAP6-38, as described above) and observe subsequent pERK levels in the presence
and absence of stress. Pretreatment with PACAP6-38 prior to footshock significantly
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lessened pERK expression in cocaine responders (compare Figure 3.5 (A, C, I)). In
cocaine responders, compared to no-fooshock (Figure 3.5 (B, D, I)), footshock exposure
increased the number of activated phosphorylated ERK neurons (Figure 3.5 (A, I)), but
pretreatment with PACAP6-38 blocked the ability of footshock stress to induce ERK
phosphorylation in BNST neurons (Figure 3.5 (C, I)). The increase in footshockstimulated ERK activation was attenuated approximately 60-70% by PACAP6-38
(vehicle + footshock = 88.58 ± 12.45 cells vs. PACAP6-38 + footshock = 33.9 ± 9.50
cells, [bonferroni’s m.c. t(13)=3.92, p<0.05]). There was a significant interaction between
pre-treatment (vehicle vs. PACAP6-38) by stress (footshock vs. no footshock),
F(2,13)=2.43, p<0.05. While there was no difference between pERK expression in
cocaine responders who received no-footshock (vehicle + no footshock = 33.75 ± 7.23
cells; PACAP6-38 + no-footshock = 32.44 ± 4.89 cells), there was a significant
difference in pERK expression in cocaine responders regardless of infusion or stress
treatment compared to cocaine non-responders: cocaine non-responders had very little
pERK expression in the BNST (group means ±SEM: vehicle + footshock = 17.5 ± 5.63;
PACAP6-38 + footshock = 3.25 ±0.83; vehicle + no-footshock = 5.75 ±1.49; PACAP638 = 9.0 ± 3.24). Hence, footshock only increases pERK if the animal is cocaine
experienced, a finding that may be PACAP dependent. This data suggests a permanent
change in the PACAP system following cocaine exposure.

There was very little pERK expression overall in cocaine non-responders (see Figure 3.5
(E-H, J), such that no significant differences were found between groups who received
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vehicle or PACAP6-38 infusion or footshock vs. no-footshock. Hence, most shockinduced pERK signaling appears to be PACAP dependent, especially when the animal is
cocaine experienced.

3.4. Discussion

In Experiment 1, we showed that BNST PAC1 receptor activation is necessary for stressinduced reinstatement, as selective PAC1 receptor agonist maxadilan infusion caused
drug-seeking on test day in the absence of stress. Here, we show that shock-induced
pERK signaling is dependent on PACAP receptor activation, especially in cocaine
responders. Endogenous BNST PACAP/PAC1 signaling is relevant in mediating stressand anxiety-induced behaviors. Hence, PAC1/VPAC2 receptor antagonism via
administration of PACAP6-38 should block related behaviors. Following a week-long
chronic variate stress paradigm, Roman et al. (2014) showed that PACAP6-38 infusions
blunted stress-induced anxiety-like responses on an elevated plus maze (EPM), blocked
anorexic-like effects, and significantly decreased stress-induced corticosterone release (a
hormone typically released in response to stress). These results suggest that PACAP is
released during footshock in cocaine experienced rats, and this release and/or its response
is potentiated by cocaine self-administration.

Blockade of PAC1/VPAC2 by PACAP6-38 also has noticeable effects outside the BNST:
in spinal cord neurons, blockade attenuates neuropathic and inflammatory pain (Davis62

Taber et al., 2008); in the BLA, PACAP6-38 blocks fear conditioning (Schmidt et al.,
2015); and intra-CeA blockade attenuates chronic-pain induced behavioral responses
(Missig et al., 2017). In the current experiment, we did see that intra-BNST infusion of
PACAP6-38 attenuated stress-induced reinstatement (replicating our prior work; Miles et
al., 2017), and reduced pERK expression after footshock exposure if the animals were
cocaine-experienced (i.e. cocaine responders). That is, when PAC1/VPAC2 receptors are
blocked, stressor exposure is no longer sufficient to reinstate drug-seeking behavior.
However, intra-BNST infusion of PACAP6-38 into cocaine non-responders had no effect
on stress-related reinstatement behaviors or pERK expression, suggesting that
endogenous PACAP signaling in animals who are not cocaine experienced may be too
low to impact BNST functions. Additionally, lack of reinstatement and noticeable
decrease of pERK expression may imply that BNST PACAP signaling modulates the
reinstatement of drug-seeking in animals who consistently lever pressed for cocaine but
does not affect pERK expression under normal conditions (i.e. if the animal is not drug
experienced). The ability of PACAP6-38 to lessen stress-induced reinstatement after a
period of chronic (10d) self-administration and extinction (20d) suggests that BNST
PACAP levels increase and remain elevated throughout the 30 total days of behavior to
facilitate the stress-induced behavioral responses.

Prior work in our laboratory has led to the hypothesis that drug-use activated PACAP
systems upstream of CRH in the oval BNST which mediates CRH in the PVN to
stimulate a stress response. If true, administration of PAC1/VPAC2 antagonist PACAP663

38 infusion into the BNST may block receptors responsible for maintaining downstream
PVN CRH (a necessary component of the stress response). Support for this idea comes
from studies conducted by Stewart (2000) describing the role of CRH in stress-induced
reinstatement: CRH receptor antagonist, D-Phe CRH blocks footshock-induced
reinstatement. The present study (and Miles et al., 2017) suggests that PACAP regulates
CRH activity in the PVN and, subsequently, behavioral stress responses.

Effects of BNST PAC1 receptor activation are likely mediated by intracellular signaling
cascades that manifest in increased pERK expression. Multiple PAC1 receptor isoforms
may be coupled to several distinct intracellular signaling pathways: G-protein coupled
activation of AC or PLC, or endosomal signaling by the PAC1 receptor itself via
receptor-arrestin scaffolding proteins. A point of convergence for these multiple
pathways may be the phosphorylation of ERK (Hammack & May, 2015). The remaining
two experiments aimed to determine the signaling mechanisms that mediate heightened
ERK phosphorylation following BNST PAC1 receptor activation in rats who undergo a
stress-induced reinstatement paradigm.
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3.5. Figures

Jugular Catheterization &
BNST Cannulation
Surgeries
Post-Op (7 days)

Test for footshock-induced
reinstatement
Cocaine SA (10 days)

Perfusion, 30
min after test

Extinction (20 days)

Intra-BNST Infusion of PACAP6-38 or
Vehicle 15 min prior to behavioral test

Figure 3.1. Timeline for Experiment 2. Jugular catheterizations and BNST cannulations
were performed concurrently in rats for self-administration and test-day infusions, as
shown in the experimental timeline. This was followed by one week of post-operative
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day.
Infusions of PACAP6-38 or vehicle treatment occurred 15 minutes prior to the animals’
reintroduction to the operant conditioning chambers on test day. During test, animals
received either footshock or no-footshock. Animals were perfused 30m after the end of
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures.

65

0.36

-0.48

0.24

-0.60

0.12
-0.72
0.00

-0.84

-0.12

-0.24

-0.36

Figure 3.2. BNST Cannula Placements.
Cannula placements are depicted above such that enclosed red dots represent a 1mm
extension beyond the tip of the cannula. Rats were included in the analysis if their
placement resided within a portion of the BNST; they were eliminated from analysis if
their cannulae placement fell outside the histological boundary of the BNST, fell within
the lateral ventricles, or if animals did not complete behavioral testing.
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Figure 3.3. Intra-BNST infusion of PACAP6-38 attenuates stress-induced
reinstatement.
(A) Self-administration training on the active lever during Experiment 4; inactive lever
presses remained uniformly low throughout acquisition. A median split analysis for total
lever presses over 10d was used to separate cocaine responders (M=95.14, SD=2.98)
from non-responders (M=37, SD=0.68). (B) Extinction training during Experiment 4.
Extinction sessions occurred during the 20 days after self-administration training. (C) To
determine whether PAC1 receptor activation is necessary during reinstatement to drugseeking, we infused PAC1 receptor antagonist PACAP6-38 or vehicle into the BNST
paired with footshock or no footshock

during the test phase of the reinstatement
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procedure. Stressor exposure only caused reinstatement to extinguished drug-seeking in
cocaine responders who received intra-BNST vehicle solution; PACAP6-38 pretreatment completely attenuated drug-seeking behavior following stressor exposure. (D)
There were no differences between the last day of extinction and test day in cocaine nonresponders, and no effect of vehicle vs. PACAP6-38 infusion. Group n’s are as follows:
cocaine responders-noshock-vehicle, n=4; cocaine responders-noshock-PACAP6-38,
n=4; cocaine responders-shock-vehicle, n=4; cocaine responders-shock-PACAP6-38,
n=4; cocaine non-responders-noshock-vehicle, n=2; cocaine non-responders-noshockPACAP6-38, n=3; cocaine non-responders-shock-vehicle, n=2; cocaine non-respondersshock-PACAP6-38, n=3. Data represent mean lever presses ± SEM.
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Figure 3.4. Total cocaine infusions over 10d acquisition.
Animals in groups Vehicle/Footshock (M=52.0, SD=5.91), Vehicle/NoFootshock
(M=62.6, SD=5.92), PACAP6-38/Footshock (M=47.6, SD=7.35), and PACAP638/NoFootshock (M=48.6, SD=9.32) received the same amount of cocaine during
acquisition, indicating that reinstatement was elicited by footshock stress rather than total
cocaine intake during acquisition.
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Figure 3.5. PAC1 receptor activation and ERK activation participate in BNSTmediated reinstatement to drug-seeking.
Compared to no-stress (B, I), footshock stress increased the number of activated
phosphorylated ERK neurons in cocaine responders (A, I). Pretreatment with PAC1
antagonist, PACAP6-38, blocked the ability of footshock to induce ERK phosphorylation
(C, I). Cocaine non-responders had uniformly low levels of pERK expression regardless
of shock or infusion treatment (E, F, G, H, J). Scale bar: 100 µm. Data represent mean
cell number ±SEM.
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CHAPTER 4: BLOCKADE OF CLATHRIN MEDIATED ENDOCYTOSIS BY
PITSTOP2 ATTENUATES STRESS-INDUCED REINSTATEMENT TO
COCAINE-SEEKING

4.1. Introduction
In Experiment 1 (Chapter 2), we successfully mimicked footshock-induced reinstatement
using selective PAC1 receptor agonist maxadilan. Furthermore, PAC1 receptor activation
has been shown to facilitate downstream signaling cascades responsible for stressassociated behaviors. And, footshock-induced pERK expression following cocaine selfadministration is dependent on PACAP receptor activation. However, PAC1 signaling is
complex (see Hammack & May, 2015; Figure 1.5), and can promote short- and long-term
neuronal activity. Notably, PAC1 has been shown to activate intracellular signaling
cascades that potentiate plasticity in regions like the BNST, perhaps in response to stress
or drug self-administration. Hence, PAC1 receptor isoforms can differentially couple to
Gαs and Gαq to initiate adenylate cyclase (AC) or phospholipase C (PLC), both of which
potentiate ERK signaling. Additionally, the PAC1 receptor may bind to arrestin
molecules acting as scaffolding for enzymes related to subsequent ERK activation.
Binding to a β-arrestin complex promotes endosome signaling following internalization
of the receptor itself (May & Parsons, 2017; Hammack & May, 2015). Indeed, Merriam
and colleagues (2013) demonstrated PAC1 receptor internalization following PACAP
treatment at 37°C, in EGFP-PAC1 tagged HEK293 cells; notably, pre-treatment with
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clathrin-mediated endocytosis inhibitor Pitstop2 blocked this internalization and
subsequently lessened downstream ERK activation (Merriam et al., 2013). This suggests
that PAC1 receptor internalization and the effects on downstream ERK pathways
(following footshock-induced PACAP release) may be critical for stress- and PACAPinduced effects.

PAC1 receptor internalization as a means of ERK phosphorylation
As mentioned, there are several potential intracellular routes to ERK activation, but
recent studies have implicated PAC1 receptor internalization via clathrin-mediated
endocytosis by β-arrestin proteins as an important mediator of downstream cell signaling.
Notably, the presence of PACAP in cell culture experiments with HEK PAC1-EGFP
cells facilitated PAC1 receptor internalization (May et al., 2014; May & Parsons, 2017).
However, pre-treatment with clathrin-mediated endocytosis inhibitors Pitstop2 or
dynasore inhibited PAC1 internalization but had no effects on PACAP generation of
cAMP.

In CeA, Pitstop2 pre-treatment markedly blocked PACAP-mediated c-fos expression and
ERK phosphorylation (Missig et al., 2017). Furthermore, inhibition of clathrin-mediated
endocytosis reduced PACAP-induced hypersensitivity in a model of chronic pain
(chronic constriction injury of the sciatic nerve; CCI), which may suggest that PAC1
receptor internalization and subsequent ERK activation can modulate nociception.
Recently, when tested in HEK cells expressing PAC1-type receptors, endocytosis
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blockers (Pitstop2 and Dynasore) reduced ERK expression in the presence of PACAP
(May et al., 2014). HEK cells expressing VPAC-type receptors also exhibited diminished
pERK levels after pretreatment with endocytosis blockers in the presence of PACAP
(Anne Linden & Victor May, personal communication), suggesting that PACAP actions
at both VPAC- and PAC1-type receptor activation results in elevated pERK that can be
eliminated with the addition of an endocytosis blocker (perhaps due to the global nature
of endocytosis blockers, discussed below).

Chapter 2 demonstrated that selective activation of the PAC1 receptor mimicked stressand PACAP-induced reinstatement, and Chapter 3 showed that shock-induced pERK
signaling is dependent on PACAP receptor activation. Hence, we hypothesized that
activation of PAC1 receptors facilitates downstream signaling cascades responsible for
relapse-associated behaviors. This experiment therefore sought to block a downstream
target of the PAC1 receptor, specifically the β-arrestin complex partially responsible for
facilitating PAC1 receptor internalization, in an effort to elucidate the signaling pathway
involved in stress-induced reinstatement. Importantly, we hoped to determine whether
endosomal signaling of the PAC1 receptor mediated behavioral consequences of stressor
exposure to lead to relapse-related actions. Indeed, since PAC1 endocytosis may lead to
the direct activation of signaling molecules like MEK through the activation of the
receptor-arrestin complex, this study aimed to specifically inhibit the complex using
clathrin-mediated endocytosis inhibitor Pitstop2. We suggest that stress-induced
reinstatement is mediated partially by footshock-induced PAC1/PACAP receptor
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activation, and blockade of downstream targets of this receptor/peptide binding, such as
the receptor-arrestin complex, will attenuate stress-induced reinstatement when paired
with stress.

4.2. Materials & Methods
Subjects, Apparatus & Surgical Procedures
Thirty naïve male Sprague Dawley rats of the same age and from the same vendors as
those in Experiment 1 were used in this study. They were maintained under the same
conditions and utilized the same apparatus as that used in Experiment 1. All animals
received both the jugular catheterization and BNST cannulation surgeries as described in
Chapter 2.

Cocaine Self-Administration (Acquisition)
As in Experiment 1 (Chapter 2), animals were allowed to lever press for cocaine
hydrochloride (3.0mg/ml, obtained from the same vendor as in Experiment 1) during
daily 1 h sessions for 10 days according to a fixed ratio schedule of reinforcement.
Animals received the same conditions inside the operant chamber as animals in
Experiment 1.

Extinction
Extinction sessions proceeded as described in Experiment 1.
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Reinstatement
On the day following the last day of extinction, rats were split into four groups,
counterbalanced for order and time of testing, that received different treatments. Rats
received an infusion into the BNST of clathrin-mediated endocytosis inhibitor Pitstop2
(30 µM) or equivolume 0.05% BSA saline vehicle paired with footshock (intermittent 5 s
2mA footshock over 1h; average of 6 shocks per test session per animal) or no footshock
to observe the effects of inhibition on downstream PAC1 receptor targets.

Directly following bilateral infusion, animals were placed into the operant conditioning
chambers and allowed to lever press. Active and inactive levers were available, and
presses recorded, but no drug was available during test day. Animals were broken into
groups based on three factors: Cocaine Responders vs Non-Responders, Footshock vs.
No Footshock, and Pitstop2 vs. Vehicle solution. Hence, the groups were as follows:
Responder-shock-Pitstop2, n=3; Responder-Shock-Vehicle, n=3; Responders-NoShockPitstop2, n=3; Responders-NoShock-Vehicle, n=5; NonResponders-Shock-Pitstop2, n=4;
NonResponders-Shock-Vehicle, n=3; NonResponders-NoShock-Pitstop2, n=3; and
NonResponders-NoShock-Vehicle, n=3.

Histological and Immunohistochemistry Procedures
Thirty minutes after the end of the test session (i.e. 1.5 hours after intra-BNST infusion
and the start of behavioral testing), animals were anesthetized and perfused transcardially
with saline followed by 4% paraformaldehyde. Brains were postfixed for 24 h, washed
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and equilibrated in 30% sucrose before embedding in optimal cutting temperature (OCT)
compound (ThermoFisher Scientific, Waltham, MA) for cryosectioning (40 µm). All
sections were mounted onto subbed slides, permabilized with 0.3% Titron X-100,
blocked with 1% BSA, and incubated in primary antibody (1:1000, Phospho-p44/42
MAPK (Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology,
Danvers, MA) for visualization of pERK using species specific AlexaFluor 488 (1:500;
4hr; ab150077; Abcam).

Image Analysis
Micrographs were obtained using an Olympus fluorescence microscope with identical
parameters for each image. For quantification of BNST pERK immunoreactivity, the
corresponding BNST fields in the different brains were identified using the anterior
commissure, lateral ventricles, and outer field of the caudate putamen as reference points;
area of threshold was used as an indicator of relative fluorescence from same sized fields.
For enumeration of BNST pERK in fixed areas, a semi-autonomous cell counting method
was performed in StereoInvestigator (MBF Biosciences, Williston VT). All data
represent mean values ± SEM.

Data Analysis
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM (version
6). Two-way analysis of variance (ANOVA) was performed to examine main effects and
interactions, and Bonferroni’s multiple comparison tests were used to compare different
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groups for all experiments, except where indicated.

4.3. Results
Since PAC1 endocytosis may lead to the direct activation of signaling molecules like
MEK through the activation of the receptor-arrestin complex, we sought to specifically
inhibit this complex using clathrin-mediated endocytosis inhibitor Pitstop2. Previous
studies have implicated endogenous CeA PAC1 receptor endosomal ERK signaling in
pain

pathways,

and

Pitstop2

pretreatment

blocked

PACAP-mediated

ERK

phosphorylation. Behaviorally, the inhibition of clathrin-mediated endocytosis by
Pitstop2 reduced PAC1/PACAP-induced thermal hypersensitivity in Hargreaves test
(Missig et al., 2017). Hence, we hypothesized that stress-induced reinstatement is
mediated partially by PAC1/PACAP receptor activation, and blockade of downstream
targets of this receptor/peptide binding, such as the receptor-arrestin complex, will
attenuate stress-induced reinstatement when paired with stressor exposure.

Figure 4.1 illustrates the timeline of events for Experiment 3. Data from 27 animals were
used in the analyses for the tests for reinstatement, as post-test histological examination
of injection sites for these rats were found to be placed appropriately in the BNST. Two
animals had improperly placed cannula and were excluded from the analysis; one lost his
skullcap during infusion and was immediately sacrificed and eliminated from all
analyses. Figure 4.2 portrays the distribution of cannula placements in analyzed animals.
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Self-Administration Training
Immediately after the last acquisition session, a median split analysis for total lever
presses over 10d was used to separate cocaine responders (M=88.5, SD=6.12) from
cocaine non-responders (M=25.25, SD=9.14). Cocaine responders self-administered an
average [mean (±SEM)] of 8.85 (±2.45) infusions of cocaine HCL per hour,
0.75mg/kg/infusion, over the 10 days of acquisition; cocaine non-responders selfadministered an average of 2.5 (±2.18) infusions per hour, 0.75mg/kg/infusion, over the
same 10d period. The mean (±SEM) number of responses made on the inactive lever
throughout acquisition was uniformly low across responders and non-responders per
session, 1.13 (±0.43) (Figure 3.3 (A)).

Extinction
By the end of extinction, all rats had reached ≤ 5 responses; inactive lever responses
remained uniformly low throughout extinction. The mean (±SEM) number of responses
made on the active and inactive levers on the last day of extinction and during the test for
reinstatement are shown in Figure 3.3 (B).

Reinstatement
Bilateral intra-BNST infusion of clathrin-mediated endocytosis inhibitor Pistop2
significantly attenuated active lever responding in the test session of cocaine responders
after stressor exposure. Only rats that received vehicle solution paired with footshock
increased responding on the active lever during test for reinstatement (consistent with
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prior data). No significant differences in responding were found between animals infused
with BSA vehicle solution. A treatment (Pitstop2, vehicle) by session (last day of
extinction, test) ANOVA supported these observations. Regarding cocaine responders,
there was a significant effect of session (F(1,6)=5.53, p<0.05), and significant
interactions between session and shock (F(1,6)=12.86, p<0.01), and session and infusion
treatment (F(1,6)=1.67, p<0.05). Finally, there was a significant session by shock by
infusion treatment interaction (F(1,6)=13.12, p<0.01), consistent with the fact that only
animals that received the footshock and vehicle infusion demonstrated stress-induced
reinstatement. Notably, cocaine responders in both the vehicle and Pitstop2 group
received the same amount of cocaine during acquisition (Figure 3.4), indicating that
reinstatement was elicited by footshock exposure rather than total cocaine intake during
acquisition. Pitstop2 blocked reinstatement of extinguished cocaine seeking when rats
were exposure to a shock stressor. The post hoc analyses comparing Pitstop2 and vehicle
infusion on total responses on the active lever after footshock exposure revealed
significantly less responding in the Pitstop2 condition (p<0.01).

Additionally, the

number of responses on the active lever in the no-footshock condition after injections of
Pitstop2 did not differ from lever press activity after vehicle infusion. Pitstop2 did not
alter responding on the inactive lever (F(1,6)=3.40, NS) and responses remained low
during testing.

Regarding cocaine non-responders, there was no significant difference in any condition
(footshock vs. no footshock; Pitstop2 vs. vehicle) compared to the last day of extinction.
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Hence, Pitstop2 appears only to block stress-induced reinstatement if the animal is
cocaine experienced.

BNST ERK Signaling in Stress-Induced Reinstatement
As mentioned above, there are several mechanisms by which PAC1 receptors may
activate MEK/ERK pathways, including PKA and PKC activation and endosomal
signaling. Importantly, ERK phosphorylation has been attenuated by blocking PAC1
receptor internalization into signaling endosomes (Merriam et al., 2013). Here, consistent
with cell culture data (May et al., 2014; May & Parsons, 2017) and analysis in a chronic
constriction injury model (Missig et al., 2017), pretreatment with Pitstop2, an inhibitor of
clathrin-mediated endocytosis, prior to footshock, completely ablated pERK expression
in cocaine responders (Figure 3.5, compare (A) and (C)). In cocaine responders,
compared to no-footshock, footshock stress increased the number of activated
phosphorylated ERK neurons (Figure 3.5, compare (A) and (B)). Pretreatment with
Pitstop2 blocked the ability of footshock stress to induce ERK phosphorylation in BNST
neurons (Figure 3.5, (C)). Indeed, the increase in footshock-stimulated ERK activation
was attenuated approximately 80-90% by Pitstop2 (vehicle + footshock = 122.22 ± 17.3
cells vs. Pitstop2 + footshock = 11.2 ± 2.54 cells, [Bonferroni’s m.c. t(15)=5.57,
p<0.0001]). Furthermore, there was a significant interaction between pre-treatment
(vehicle vs. Pitstop2) by stress (footshock vs. no footshock) interaction, F(2,15)=5.19,
p<0.05. Notably, there was also a difference in pERK expression in animals who did not
receive stressor exposure, but were cocaine experienced (Figure 3.5, compare (B) and
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(F); vehicle + no-shock = 43.2 ± 12.4 cells vs. Pitstop2 + no-shock = 14.44 ± 17.3 cells,
[Bonferroni’s m.c. t(15)=1.23, NS]). Figure 3.5 (I) and (J) shows quantified pERK levels
in cocaine responders vs. non-responders after footshock vs. no-footshock and vehicle vs.
Pitstop2 pretreatment.

Regarding cocaine non-responders, there was no significant difference between any of
the conditions (footshock vs. no-footshock or vehicle vs. Pitstop2; Figure 3.5 (E-H, J)).
Interestingly, there is a slight, but insignificant, increase in pERK expression in cocaine
non-responders who receive vehicle treatment paired with footshock, likely due to the
footshock stress prior to perfusion for tissue harvest. This is notable, as footshock only
appears to significantly increase pERK if the animal is cocaine experienced, a finding
that may be PACAP dependent. Average cell counts for cocaine non-responders are as
follows: group vehicle + shock = 45.89 ± 19.84; shock + Pitstop2 = 5.08 ± 4.32; noshock + vehicle = 14.44 ± 7.89; no-shock + Pitstop2 = 7.44 ± 2.32. This data may suggest
a permanent change in the PACAP system following cocaine exposure.

4.4. Discussion
In Experiment 1, we showed that BNST PAC1 receptor activation is necessary for stressinduced reinstatement, as selective PAC1 receptor agonist maxadilan infusion caused
drug-seeking on test day in the absence of stress. Then, Experiment 2 showed that shockinduced pERK signaling is dependent on PAC1 receptor activation. Here, we show that
blockage of clathrin-mediated endocytosis

by Pitstop2 attenuated drug-seeking in the
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presence of footshock stress. Furthermore, we saw a decrease in pERK activation
following footshock stress after Pitstop2 pretreatment, indicating an importance of
downstream PAC1 mechanisms in ERK activation that may lead to further neuronal
activity responsible for relapse states.

As a group, G-protein coupled receptors (GPCRs) function primarily to transduce
extracellular stimuli into intracellular signals. Following agonist binding to the receptor
(PACAP to PAC1), a change in the conformation of the PAC1 receptor occurs that
facilitates activation of downstream pathways. This signaling may be attenuated by
internalization of the receptor (an action likely facilitated by arrestin binding) or removal
of the agonist. Additionally, PAC1 internalization may facilitate sustained MEK/ERK
activation. Here, we blocked clathrin-mediated endocytosis and attenuated stress-induced
reinstatement of drug-seeking in addition to decreasing ERK phosphorylation. Recently,
Missig et al. (2017) showed that Pitstop2 pretreatment blocks PACAP-stimulated
receptor internalization and behavioral manifestations of pain in a chronic constriction
injury model. Finally, in an electrophysiology preparation, Pitstop2 ablates PACAPinduced increases in cardiac neuron excitability (Merriam et al., 2013; May & Parsons,
2017).

The ability to inhibit clathrin-mediated endocytosis would benefit studies in both cell
biology and in the clinical realm. The Pitstop compounds, while they provide some
insights into cell physiology, also have their drawbacks: Pitstop2 is a global inhibitor of
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clathrin-mediated endocytosis and is therefore not selective to the PAC1 receptor. Willox
et al. (2014) tested the extent of Pitstop2 non-specificity and found that the compound
acts very differently in vivo than in cell culture. In vitro, Pitstop2 binds to the receptor
pocket that accommodates clathrin-box motif peptides, whereas the compound does not
bind (or binds with lower affinity) at this site in vivo, lessening the effects of Pitstop2. In
the current experiment, there were no changes between vehicle and Pitstop2-treated
cocaine non-responders that did not receive footshock, so we may reasonably conclude
that clathrin-mediated endocytosis is required for BNST PACAP signaling to fully induce
ERK phosphorylation and stress-induced reinstatement.

While PACAP mediated effects have relatively gradual onsets (see Shimizu et al., 2004),
activation of the PACAP/PAC1 compound stimulates ERK for long durations (Clason et
al., 2016). Studies by Walker and Davis showed that the BNST likely mediates responses
to sustained, fear-evoking stimuli (akin to anxiety), rather than short, phasic fear-evoking
stimuli (likely mediated by CeA; Davis et al., 2010; Walker et al., 2009). Hence, BNST
appears to play a role in sustained responding. Indeed, one possible role for PAC1 in
addiction states is that receptor internalization may provide a mechanism to allow for
sustained ERK activation. Theoretically, sustained ERK signaling could have
implications in PACAP/PAC1 mediated plasticity that promotes neurochemical changes
in response to drug use, stress, or even trauma that could lead to sustained
psychopathologies.
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The PAC1 receptor can also be coupled to both Gs and Gq to activate adenylyl cyclase
(AC) and phospholipase C (PLC), respectively (for review, see Hammack & May, 2015).
Increased AC activity results in heightened cAMP expression which engage PKAdependent or -independent pathways leading to ERK phosphorylation and subsequent
signaling. In contrast, increased PLC activity leads to IP3 and DAG activation, which
stimulates PKC mechanisms leading to ERK phosphorylation. Hence, these two
alternative pathways stimulate mitogen-activated protein kinase (MAPK)/ERK cascades
(that later help facilitate intra-cellular function) without associating arrestin scaffolding
proteins that aid in receptor internalization. Thus, if we had not seen an attenuation of
drug-seeking on test day in cocaine responders who received Pitstop2 pretreatment paired
with stressor exposure, it might have been possible that endosomal signaling mediated by
clathrin dependent endocytosis was not involved in stress-induced reinstatement. Since
we did observe a decrease in active lever press responding on test day in this group of
animals, we next blocked MEK signaling, further downstream of the PAC1 receptor in
the intracellular signaling cascade.
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4.5. Figures
Jugular Catheterization &
BNST Cannulation
Surgeries
Post-Op (7 days)

Test for footshock-induced
reinstatement
Cocaine SA (10 days)

Perfusion, 30
min after test

Extinction (20 days)

Intra-BNST Infusion of Pitstop2 or Vehicle
15 min prior to behavioral test

Figure 4.1. Timeline for Experiment 3. Jugular catheterizations and BNST cannulations
were performed concurrently in rats for self-administration and test-day infusions, as
shown in the experimental timeline. This was followed by one week of post-operative
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day.
Infusions of Pitstop2 or vehicle treatment occurred 15 minutes prior to the animals’
reintroduction to the operant conditioning chambers on test day. During test, animals
received either footshock or no footshock. Animals were perfused 30m after the end of
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures.
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Figure 4.2. BNST Cannula Placements.
Cannula placements are depicted above such that enclosed red dots represent a 1mm
extension beyond the tip of the cannula. Rats were included in the analysis if their
placement resided within a portion of the BNST; they were eliminated from analysis if
their cannulae placement fell outside the histological boundary of the BNST, fell within
the lateral ventricles, or if animals did not complete behavioral testing.
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Figure 4.3. Intra-BNST Pitstop2 infusion attenuates stress-induced reinstatement to
cocaine-seeking.
(A) Self-administration training on the active lever during Experiment 2; inactive lever
presses remained uniformly low throughout acquisition. A median split analysis for total
lever presses over 10d was used to separate cocaine responders (M=88.5, SD=6.12) from
non-responders (M=25.25, SD=9.14). (B) Extinction training during Experiment 2.
Extinction sessions occurred during the 20 days after self-administration training. (C) To
determine whether PAC1 receptor activation is necessary during reinstatement to drugseeking, we infused clathrin-mediated endocytosis inhibitor Pitstop2 or vehicle into the
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BNST paired with footshock or no footshock during the test phase of the reinstatement
procedure. Stressor exposure only caused reinstatement to extinguished drug-seeking in
cocaine responders who received intra-BNST vehicle solution; Pitstop2 treatment
completely attenuated drug-seeking behavior following stressor exposure. (D) There were
no differences between the last day of extinction and test day in cocaine non-responders,
and no effect of vehicle vs. Pitstop2 infusion. Group n’s are as follows: cocaine
responders-noshock-vehicle, n=5; cocaine responders-noshock-Pitstop2, n=3; cocaine
responders-shock-vehicle, n=3; cocaine responders-shock-Pitstop2, n=3; cocaine nonresponders-noshock-vehicle,

n=3;

cocaine

non-responders-noshock-Pitstop2,

n=3;

cocaine non-responders-shock-vehicle, n=3; cocaine non-responders-shock-Pitstop2,
n=4. Data represent mean lever presses ± SEM.
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Figure 4.4. Total cocaine intake over 10d acquisition.
Cocaine responders in both the footshock/no-footshock and vehicle/Pitstop2 groups
received the same amount of cocaine during acquisition. Vehicle/Footshock (M=34.2,
SD=6.97); Vehicle/NoFootshock (M=31.6, SD=8.51); Pitstop2/Footshock (M=37.2,
SD=7.86); Pitstop2/NoFootshock (M=29.2, SD=5.76). This indicates that reinstatement
was elicited by footshock stress (rather than total cocaine intake during acquisition), and
subsequently blocked by Pitstop2 pre-treatment.
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Figure 4.5. PACAP receptor internalization and ERK activation participate in
BNST-mediated reinstatement to extinguished drug seeking.
Compared to no-stress (B), footshock stress increased the number of activated
phosphorylated ERK neurons (A) when paired with a vehicle infusion in cocaine
responders. Pretreatment with clathrin-mediated endocytosis inhibitor Pitstop2 (B)
blocked the ability of stress to induce ERK phosphorylation in BNST neurons. Cocaine
non-responders expressed very little pERK regardless of footshock stress or infusion
treatment (E, F, G, H, J). Scale bar: 100 µm. Data represent mean cell number ±SEM.

92

CHAPTER 5: INHIBITION OF MEK PATHWAY ATTENUATES STRESSINDUCED REINSTATEMENT TO COCAINE SEEKING.

5.1. Introduction
The communication of extracellular signals (i.e. hormones, mitogens) to internal cellular
environments happens through an intricate messaging system mediated by the binding of
ligands and subsequent activation of specific transmembrane receptors which further
submit signals through intracellular pathways. These pathways consist of interacting
proteins and include the mitogen-activated protein kinase (MAPK) cascade. Signal
transmission by MAPK proteins is often initiated by the activation of a small g-protein.
In the case of the PAC1 receptor, Gαs activates phospholipase C (PLC) which stimulates
protein-kinase C (PKC) dependent signaling events to activate MAPK-extracellular
signal-related kinase (MEK) which further stimulates phosphorylation of ERK.
Additionally, Gαq can couple to adenylyl cyclase (AC) to activate protein kinase A
(PKA) which also activates MEK pathways, leading to phosphorylation of ERK (for
review, see Hammack & May, 2015). Importantly, the ERK family represents a critical
subfamily of MAPKs, as stimulation targets transmembrane proteins and transcription
factors (Chen et al., 2013) The mitogen-activated protein kinases are a well conserved
family of kinases involved in numerous cellular processes including proliferation,
motility, development, and differentiation (Shaul & Seger, 2007).
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PD98059 is a highly selective inhibitor of MEK activation and, subsequently, the MAPK
signaling cascade (Crews et al., 1992; Rosen et al., 1994; Cowley et al., 1994), and acts
by preventing activation of MEK1 and MEK2 by upstream proteins. It has been widely
used across scientific fields and has been shown to accelerate differentiation (Hotokezaka
et al., 2002), prevent degeneration (Rapoport & Ferreira, 2000), attenuate synaptic
plasticity (Coogan et al., 1999), promote cell migration (Zhao et al., 2017), and influence
immune factors that mediate behavior (Rojewska et al., 2015). Hence, the MAPK
signaling pathway can facilitate numerous intracellular events, and is an important
proposed target in the treatment of physiological disorders. Indeed, pathway inhibitors
have been widely used to block specific pathways to observe changes in effects in
different experimental procedures. PD98059 has high selectivity for the MEK pathway,
and results in clear changes in downstream protein expression after application (Gregg &
Frazier, 2011).

In an effort to elucidate mechanisms underlying PACAP- and stress-induced cellular
responses, Clason et al. (2016) showed that PD98059 application can suppress PACAPstimulated increases in guinea pig cardiac neuron excitability (see also Tompkins et al.,
2016). Furthermore, Missig et al. (2017) showed that CeA pretreatment with PD98059
decreased PACAP-mediated c-fos and pERK immunoreactivity and heightened
nociception sensitivity: PACAP-induced responses were completely abolished by MEK
inhibition, demonstrating a necessity for PACAP/PACI signaling via ERK pathways in
amygdala pain responses. As expressed in Chapter 3, PACAP/PAC1 receptor-mediated
94

ERK activation may be largely controlled by endosomal signaling and PAC1 receptor
internalization. Indeed, blockade of receptor internalization by clathrin-mediated
endocytosis inhibitor Pitstop2 successfully attenuated both behavioral manifestations of
stress-induced reinstatement (see Figure 4.3) and subsequent ERK phosphorylation (see
Figure 4.5). Hence, endosome g-protein coupled receptor signaling via the PAC1 receptor
appears to have important physiological functions in stress-related disorders including
chronic pain and relapse to drug-use.

Together, Experiments 1, 2 & 3 (Chapters 2, 3 & 4, respectively) suggest that stressinduced reinstatement is BNST PAC1-receptor mediated and likely involves the
downstream activation of circuits associated with stress responses. In this experiment, we
sought to examine whether inhibition of MEK could mitigate stress-induced
reinstatement to drug-seeking and diminish ERK phosphorylation following stressor
exposure. As noted above, we and others have shown that PACAP signaling can activate
MEK/ERK, a key mechanism in synaptic plasticity involved in many CeA-dependent
behaviors. As the CeA and BNST share similar morphologies, we hoped to assess BNST
PAC1 receptor mechanisms in vivo and hypothesized that endogenous PACAP signaling
in the BNST and resulting PAC1 receptor-mediated ERK activation mediates stressinduced drug-seeking in rodents. As with prior experiments mentioned, we hoped to
establish whether BNST PACAP signaling via ERK could evoke stress-induced
reinstatement and utilized the MEK inhibitor PD98059 to block mitogen activated protein
kinase cascades that stem from the PAC1 receptor and may play a role in controlling cell
95

growth and differentiation. We hypothesized that MEK inhibition prior to stressor
exposure (footshock stress) would prevent stress-induced reinstatement in cocaine
experienced animals compared to animals who receive vehicle treatment infusion.

5.2 Materials & Methods
Subjects, Apparatus & Surgical Procedures
Thirty-two naïve male Sprague Dawley rats of the same age and from the same vendor as
those described in Experiments 1, 2 & 3 (Chapters 2, 3 & 4 respectively) were used in
this experiment. They were maintained under the same conditions and utilized the same
apparatus as that used in Experiments 1, 2 & 3. All animals received both the jugular
catheterization and BNST cannulation surgeries as described above.

Cocaine Self-Administration (Acquisition)
As in Experiment 1, animals were allowed to lever press for cocaine hydrochloride
(0.3mg/ml, obtained from the same vendor as in Experiment 1) during daily 1 h sessions
for 10 days according to a fixed ratio schedule of reinforcement. Animals received the
same conditions inside the operant chamber as animals in Experiment 1.

Extinction
Extinction sessions proceeded as described in Experiment 1.

Reinstatement
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On the day following the last day of extinction, rats were split into four groups,
counterbalanced for order and time of testing, that received different treatments. Rats
received an infusion into the BNST of MEK inhibitor PD98059 (20 µM, Tocris
Bioscience, Bristol, UK) or equivolume 0.05% BSA saline vehicle paired with footshock
or no footshock in an effort to observe the effects of inhibition on downstream PAC1
receptor targets. Directly following bilateral infusion, animals were placed into the
operant conditioning chambers and allowed to lever press. Active and inactive levers
were available and presses recorded, but no drug was available during the test day.
Animals were broken into groups based on three factors: Cocaine vs. Non Cocaine
responders, Footshock vs. No Footshock, and MEK inhibitor PD98059 vs Vehicle
solution. Hence, the groups were as follows: Responders-Shock-PD98059, n=4;
Responders-Shock-Vehicle, n=4; Responders-NoShock-PD98059, n=4; RespondersNoShock-Vehicle, n=4; NonResponders-Shock-PD98059, n=4; NonResponders-ShockVehicle, n=4; NonResponders-NoShock-PD98059, n=2; and NonResponders-NoShockVehicle, n=4.

Histological and Immunohistochemistry Procedures
Thirty minutes after the test session, animals were deeply anesthetized with BeuthanasiaD (sodium pentobarbital; Zoestis, Kalamazoo, MI) solution and perfused transcardially
with saline followed by 4% paraformaldehyde. Brains were postfixed for 24 h, washed
and equilibrated in 30% sucrose before embedding in optimal cutting temperature (OCT)
compound (ThermoFisher Scientific, Waltham, MA) for cryosectioning (40 µm). All
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sections were mounted onto subbed slides, permabilized with 0.3% Titron X-100,
blocked with 1% BSA, and incubated in primary antibody (1:1000, Phospho-p44/42
MAPK (Erk1/2) Rabbit monoclonal antibody, #4370 Cell Signaling Technology,
Danvers, MA) for visualization of pERK using species specific AlexaFluor 488 (1:500;
4hr; ab150077; Abcam).

Image Analysis
Micrographs were obtained using a 10x objective on an Olympus fluorescence
microscope (Nikon Instruments, Melville, NY) with identical parameters for each image.
For quantification of BNST pERK immunoreactivity, the corresponding BNST fields in
the different brains were identified using the anterior commissure, lateral ventricles, and
outer field of the caudate putamen as reference points; area of threshold was used as an
indicator of relative fluorescence from same sized fields. For enumeration of BNST
pERK in fixed areas, a semi-autonomous cell counting method was performed in
StereoInvestigator (MBF Biosciences, Williston, VT). All data represent mean values ±
SEM.

Data Analysis
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM (version
6). Two-way analysis of variance (ANOVA) was performed to examine main effects and
interactions, and Bonferroni’s multiple comparison tests were used to compare different
groups for all experiments, except where indicated.
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5.3. Results
Together, the first three experiments suggest that stress-induced reinstatement is BNST
PAC1-receptor mediated and likely involves the downstream activation of circuits
associated with stress responses (see Figure 1.5). In this experiment, we examined
whether inhibition of MEK mitigated stress-induced reinstatement to drug seeking. We
and others have shown that PACAP signaling can activate mitogen-activated protein
kinase/ERK, a key mechanism in synaptic plasticity and involved in many CeAdependent behaviors (see Battle et al., 2016; Rosas et al., 2017; Huynh et al., 2017;
Huang & Lin, 2006; Herry et al., 2006; Missig et al., 2017). Furthermore, May & Parsons
(2017) recently suggested that PAC1 receptor endocytosis may be critical for PAC1
signaling (see Chapter 4) and subsequent activation of downstream signaling molecules,
such as MEK. Recently, Missig et al., (2017) demonstrated that CeA pretreatment with
MEK

inhibitor

PD98059

significantly

attenuated

PACAP-stimulated

thermal

hypersensitivity, indicating that ERK activation may be an essential component of
PACAP-instigated CeA activity. As the CeA and BNST share similar morphologies, we
assessed BNST PAC1 receptor mechanisms in vivo and hypothesized that endogenous
PACAP signaling in the BNST and resulting PAC1 receptor-mediated ERK activation
mediates stress-induced reinstatement of drug seeking in rodents. Hence, we sought to
establish whether BNST PACAP signaling via ERK could evoke stress-induced
reinstatement and utilized the MEK inhibitor PD98059 to block mitogen activated protein
kinase cascades that stem from the PAC1

receptor and may play a role in controlling
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cell growth and differentiation.

BNST PACAP signaling facilitates stress-induced reinstatement to extinguished cocaine
seeking
Figure 5.1 illustrates a timeline of events for Experiment 4. Data from 30 animals were
used in the analyses for the tests for reinstatement, as post-test histological examination
of injection sites for these rats were found to be placed appropriately in the BNST. One
animal had an improperly placed cannulae, and another died during extinction training;
these animals were excluded from all analyses. Figure 5.2 portrays the distribution of
cannula placements in analyzed animals.

A median split analysis for total lever presses over 10d was used to separate cocaine
responders (M=36.85, SD=6.61) from non-responders (M=8.45, SD=1.12). Cocaine
responders lever pressed almost solely on the active lever that produced cocaine delivery;
hence, active and inactive lever presses differed by the end of acquisition (Figure 5.3
(A)). In contrast, cocaine non-responders did not consistently press the active lever, and
there was no significant difference in responding on the active vs. inactive levers during
acquisition. By the end of extinction, all animals had reached ≤ 5 responses on the active
lever (Figure 5.3 (B)); inactive lever presses remained uniformly low throughout
extinction. The mean (± SEM) number of responses made on the active and inactive
levers on the last day of extinction and during the test for reinstatement is shown in
Figure 5.3 (C, D).
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A repeated measures ANOVA for inactive lever press responses did not reveal significant
results. Regarding active lever presses, there was a significant main effect of session
between the last day of extinction and testing (F(3, 16) = 6.33, p<0.01) in cocaine
responders. There were also significant interactions between session and shock
(F(1,16)=9.73, p<0.05) and session and infusion treatment (F(1, 16)=11.56, p<0.01).
Finally, there was a significant session by shock by infusion treatment interaction, (F(3,
16)=11.46, p<0.001), consistent with the fact that only cocaine-responding animals who
received the footshock and vehicle infusion demonstrated stress-induced reinstatement.
Importantly, animals in both the vehicle and PD98059 groups received the same amount
of cocaine during acquisition (Figure 5.4), indicating that reinstatement was elicited by
footshock exposure rather than total cocaine intake during acquisition. There were no
significant differences between the last day of extinction and test in cocaine nonresponders, nor were there any significant effects of infusion treatment or stressor
exposure. Hence, PD98059 blocked reinstatement of extinguished cocaine seeking when
the rats were exposed to a stressor only if the animals had successfully learned the leverpress/cocaine-infusion association. The post hoc analysis comparing antagonist and
vehicle infusion on total responses on active lever responses after footshock exposure
revealed significantly less responding in the PD98059 condition (p<0.05). Furthermore,
the number of responses on the active lever in the no-footshock conditions after
injections of PD98059 did not differ from lever press activity after vehicle infusion in
either cocaine responders or non-responders. Neither the MEK inhibitor nor the vehicle
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treatment altered responding on inactive lever presses (F(1,16)=4.23, NS) and responses
remained uniformly low during testing.

BNST MEK/ERK signaling in stress-induced reinstatement
As mentioned above, the effects of BNST PAC1 receptor activation are likely mediated
by intracellular signaling cascades that manifest in increased pERK expression.
Footshock paired with vehicle treatment significantly elevated pERK levels in cocaine
responders 30 min after test (F(1,12)=5.01, p<0.01; Figure 5.5 (A, I)). Footshock induced
a robust increase in the number of pERK cells in the anterolateral BNST in cocaine
responders, with almost no pERK labeling in non-responders under the same conditions
(main effect of stress, F(1,12)=5.16, p<0.05; Figure 5.5 (E, J)). While footshock appears
to result in marked increases in BNST pERK immunoreactivity, pretreatment with MEK
inhibitor PD98059 completely abolished the footshock-stimulated response; hence, where
we would expect to see high levels of pERK cells due to footshock stress, there was very
little expression (vehicle + footshock =105.33 ± 17.76 vs. PD98059 + footshock = 5.75 ±
4.32, [bonferroni’s m.c. t(14)=4.12, p<0.001]; Figure 5.5 (C, I)). Interestingly, some
pERK expression was observed in cocaine responders who received vehicle treatment
and no-footshock (Figure 5.5 (B, I)), suggesting that there may be a permanent change in
the PACAP system (i.e. sensitization) following cocaine exposure. In animals who did
not receive footshock stress, pERK levels were significantly lower in those who received
PD98059 compared to vehicle treatment (F(1,12)=4.71, p<0.05), demonstrating that
PD98059 may block all MEK in the area after infusion (vehicle + no-footshock = 39.01 ±
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5.83 vs. PD98059 + no-footshock = 5.25 ± 1.40). ERK activation may be an essential
component of PACAP signaling to instigate BNST neuronal activity, and PACAP/PAC1
receptor signaling via ERK pathways may be critical to stress-induced reinstatement
processes.

Regarding cocaine non-responders, there was no significant difference between any of
the conditions (footshock vs. no-footshock or vehicle vs. PD98059). Average cell counts
for cocaine non-responders are as follows: group vehicle + shock = 16.75 ± 3.33;
PD98059 + shock = 4.5 ± 1.21; vehicle + no-shock = 5.75 ± 2.15; PD98059 + no-shock =
5.5 ± 0.50 (Figure 5.5 (E-H, J)).

5.4. Discussion
In succession, these experiments establish a role for BNST PACAP signaling as a
mediator of stress-induced reinstatement to drug-seeking. In Experiment 1, we showed
that selective PAC1 agonist, maxadilan, infusion into the BNST caused reinstatement in
the absence of stressor exposure, demonstrating a critical role of the PAC1. Experiment 2
highlighted the role of PAC1 receptor activation in stress-induced pERK expression.
Then, we showed that blocking PAC1 receptor internalization by clathrin-mediated
endocytosis inhibitor Pitstop2 successfully attenuated reinstatement after stressor
exposure and ablated ERK phosphorylation. Since PAC1 receptor endocytosis is
upstream of MAPK/ERK signaling, here we blocked MEK pathways using MEK
inhibitor PD98059 and saw an abrogation of

reinstatement after footshock and a
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subsequent decrease in pERK expression. Together, these results further our
understanding of central nervous system PACAP mechanisms and point to the
PACAP/PAC1 system as an important part of the circuit that modulates stress and reward
pathways. As discussed below, the dysregulation of this system could lead to
psychopathologies related to stress and reward systems, such as relapse to drug use.

The ability of MEK inhibition to lessen BNST-mediated stress-induced pERK in parallel
with behavioral blockade of reinstatement demonstrates that PACAP/PAC1 receptor
mediated ERK activation is a critical component for BNST relapse responses. As
discussed above, there are several routes by which PAC1 receptors can activate MEK
including short-acting adenylyl clcyase/cAMP and PLC/PKC. However, recent
experiments demonstrating PAC1 receptor endocytosis (Merriam et al., 2013; Missig et
al., 2017; May & Parsons, 2017) as a means to activate MEK may represent a critical
mechanism for prolonged PAC1 receptor activation. In a similar fashion to the MEK
inhibitor, Pitstop2 blocked stress-induced reinstatement and corresponding pERK
activation. Together, this could implicate the importance of GPCRs (specifically PAC1)
and endosomal signaling in the physiology underlying relapse. In summary, g-protein
independent signaling via receptor-arrestin scaffolding and subsequent assembly of
internal signaling complexes leads to sustained MEK/ERK activation, which we can
inhibit using PD98059 or Pitstop2.

Addiction to drugs of abuse is often characterized by a chronic cycle of drug intoxication,
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withdrawal and relapse. The biological mechanisms that underlie these phases are largely
unclear but may involve signaling by ERK and other members of the MAPK family.
Indeed, cocaine exposure increases ERK activation in the VTA, amygdala, BNST, and
regions of the prefrontal cortex (Lu et al., 2006). Repeated (but not acute) cocaine
administration itself has been shown to alter ERK phosphorylation (Valijent et al., 2000)
in the striatum and nucleus accumbens, and an upstream MEK inhibitor (SL327) blocked
this effect. Brami-Cherrier et al. (2005) also reported an effect of SL327 on ERK activity,
downstream CREB activity, and the activity of an intermediary kinase in the dorsal
striatum and nucleus accumbens. Additionally, Lu et al. (2005) showed that basolateral
amygdala ERK phosphorylation was increased during periods of withdrawal.
Furthermore, Ferguson et al. (2006) found that MEK inhibition affects cocaine
conditioned place preference (CPP), and ERK1 knockout mice show enhanced morphine
CPP (Mazzucchelli et al., 2002) which suggests a role of the accumbens in cocaine
reward. Indeed, Miller & Marshall (2005) prevented CPP and blocked ERK activation by
infusing PD98059 into the accumbens. ERK activity may also contribute to psychomotor
sensitization after cocaine administration as indicated by studies completed looking at the
role of the VTA (Lu et al., 2006), as cues associated with drug use may rely on ERK for
memory consolidation. While these studies and others point to an important role of ERK
in drug self-administration, additional research is needed to elucidate the distinct roles in
ERK activity in drug acquisition, extinction (i.e. withdrawal), and relapse (cue-induced,
drug-induced, or stress-induced). The current experiment highlights an important role of
BNST PACAP/PAC1 signaling in downstream ERK signaling and subsequent cell
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proliferation, differentiation, or motility.

We have previously shown that intra-BNST PACAP6-38 (PAC1/VPAC2 receptor
antagonist) infusion attenuates stress-induced reinstatement to drug seeking (Figure 1.2;
Miles et al., 2017). We’ve also shown that PAC1 receptor activation leads to intracellular
signaling cascades that result in increased pERK expression (Chapter 2). Hence, stressinduced reinstatement, when acting through PAC1 mechanisms, should increase pERK
expression, and blockade should ablate ERK phosphorylation. Hence, Experiment 4
sought to test the effects of stressor exposure on reinstatement (effectively recapitulating
results from Miles et al., 2017) and subsequent pERK activation.
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5.5. Figures
Jugular Catheterization &
BNST Cannulation
Surgeries
Post-Op (7 days)

Test for footshock-induced
reinstatement
Cocaine SA (10 days)

Perfusion, 30
min after test

Extinction (20 days)

Intra-BNST Infusion of Maxadilan or
Vehicle 15 min prior to behavioral test

Figure 5.1. Timeline for Experiment 4. Jugular catheterizations and BNST cannulations
were performed concurrently in rats for self-administration and test-day infusions, as
shown in the experimental timeline. This was followed by one week of post-operative
recovery, 10d cocaine self-administration training, 20d extinction training, and a test day.
Infusions of PD98059 or vehicle treatment occurred 15 minutes prior to the animals’
reintroduction to the operant conditioning chambers on test day. During test, animals
received either footshock or no-footshock. Animals were perfused 30m after the end of
their behavioral test for tissue harvest and subsequent immunohistochemistry procedures.
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Figure 5.2. BNST Cannula Placements.
Cannula placements are depicted above such that enclosed red dots represent a 1mm
extension beyond the tip of the cannula. Rats were included in the analysis if their
placement resided within a portion of the BNST; they were eliminated from analysis if
their cannulae placement fell outside the histological boundary of the BNST, fell within
the lateral ventricles, or if animals did not complete behavioral testing.
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Figure 5.3. Intra-BNST infusion of MEK Inhibitor PD98059 attenuates stressinduced reinstatement.
(A) Self-administration training on the active lever during Experiment 3; inactive lever
presses remained uniformly low throughout acquisition. A median split analysis for total
lever presses over 10d was used to separate cocaine responders (M=36.85, SD=6.61)
from non-responders (M=8.45, SD=1.12). (B) Extinction training during Experiment 3.
Extinction sessions occurred during the 20 days after self-administration training. (C) To
determine whether PAC1 receptor activation is necessary during reinstatement to drugseeking, we infused mitogen activated protein kinase-ERK inhibitor PD98059 or vehicle
into the BNST paired with footshock or no

footshock during the test phase of the
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reinstatement procedure. Stressor exposure only caused reinstatement to extinguished
drug-seeking in cocaine responders who received intra-BNST vehicle solution; PD98059
pre-treatment completely attenuated drug-seeking behavior following stressor exposure.
(D) There were no differences between the last day of extinction and test day in cocaine
non-responders, and no effect of vehicle vs. PD98059 infusion. Group n’s are as follows:
cocaine responders-noshock-vehicle, n=4; cocaine responders-noshock-PD98059, n=4;
cocaine responders-shock-vehicle, n=4; cocaine responders-shock-PD98059, n=4;
cocaine

non-responders-noshock-vehicle,

n=4;

cocaine

non-responders-noshock-

PD98059, n=2; cocaine non-responders-shock-vehicle, n=4; cocaine non-respondersshock-PD98059, n=4. Data represent mean lever presses ± SEM.
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Figure 5.4. Total cocaine intake over 10d acquisition.
Animals in groups Vehicle/Footshock (M=42.71, SD=6.67), Vehicle/NoFootshock
(M=35, SD=7.07), PD98059/Footshock (M=41.5, SD=8.93), and PD98059/NoFootshock
(M=28.2, SD=4.46) received the same amount of cocaine during acquisition, indicating
that reinstatement was elicited by footshock stress rather than total cocaine intake during
acquisition.
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Figure 5.5. BNST pretreatment with MEK inhibitor PD98059 blocks stress-induced
ERK phosphorylation.
Compared to no-stress (B, D, I), footshock stress increased the number of activated
phosphorylated ERK neurons in cocaine responders (A, I). Pretreatment with MEK
inhibitor PD98059 blocked the ability of stress to induce ERK phosphorylation in BNST
neurons (C, I). In cocaine non-responders, there was a slight, but insignificant increase in
pERK expression in animals who received vehicle treatment paired with footshock (E, J),
which was blocked by PD98059 (G, J). There was very little pERK expression in cocaine
non-responders who did not receive footshock stress, regardless of infusion treatment (F,
H, J). Scale bar: 100 µm. Data represent mean cell number ±SEM.
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CHAPTER 6: GENERAL DISCUSSION

The studies in this dissertation were aimed to investigate the role of BNST PACAP
signaling in mediating stress-induced reinstatement to drug-seeking. In humans, relapse
to drug-use if often triggered by a stressful event. Furthermore, addiction is co-morbid
with many disorders of mood and anxiety, and the limited data in human drug abusers
indicate a reasonable correlation between animal models of reinstatement and drug
relapse in humans. In both humans and animals, drugs appear to activate the BNST, and
several abusive substances elicit symptoms of anxiety and panic (Singewald, Salchner &
Sharp, 2003) likely due to their activation of the HPA axis. As PACAP and PAC1
receptors are highly expressed in brain areas that modulate HPA axis activity, we propose
PACAP systems may be a critical component underlying stress-induced reinstatement
and developed these dissertation experiments to elucidate the key signaling molecules
and neural circuits involved in relapse behaviors.

The four experiments described here establish a role for BNST PACAP signaling as an
effector of physiological and behavioral manifestations of stress-induced relapse. First,
we mimicked stress-induced reinstatement by infusing selective PAC1 receptor agonist,
maxadilan, into the BNST in the absence of footshock exposure. This completely
recapitulated previous results (Miles et al., 2017) showing that PACAP infusion itself
into the BNST is sufficient to cause reinstatement to extinguished cocaine-seeking
behavior and provided evidence for PAC1 receptor activation (rather than VPAC2, which
also

binds

PACAP)

in

stress-induced

relapse processes. We then showed that
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blockade of endogenous PACAP signaling during a test for reinstatement using
PACAP6-38 attenuated stress-induced reinstatement and decreased pERK expression in
the BNST. Finally, we showed that BNST ERK activation was diminished upon
pretreatment with clathrin-mediated endocytosis inhibitor Pitstop2 (Experiment 3) or
MEK inhibitor PD98059 (Experiment 4) in conjunction with a decrease in behavioral
manifestations of reinstatement (i.e. increased lever pressing on the lever previously
associated with cocaine delivery). This finding further supports the role of PAC1 receptor
activation in relapse processes, as blockade of downstream targets both prevented relapse
and reduced ERK phosphorylation. These results aid in our understanding of central
nervous system PACAP mechanisms and demonstrate that detrimental adaptations to the
BNST PACAP system may negatively affect the outcome of individuals striving to
abstain from drug use.

6.1. The role of BNST in addiction

The BNST has been widely cited as a center for integration between stress-related
regions, including the BLA, CeA, and PVN, and reward centers like the NAcc or VTA
(Jalabert et al., 2009; Georges & Aston-Jones, 2001, 2002). Indeed, BNST function may
serve as a critical modulator of drug-related behaviors as lesions to the area prevent cueand stress-induced reinstatement to drug-seeking (Buffalari & See, 2011; McFarland et
al., 2004). Electrophysiological studies have also suggested heightened synaptic plasticity
within the BNST in response to drug use: cocaine self-administration increases
AMPA/NMDA ratios (Dumont et al., 2005),

and alcohol intake increases NMDA
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receptor efficiency (Kash et al., 2009; Wills et al., 2012), both markers of excitatory
strength. Hence, drug-taking may increase activity in excitatory synapses in the BNST,
but the specific intra-BNST regions and circuitry that underlie these enhancements has
not been well studied.
BNST afferent signaling
The BNST receives both excitatory and inhibitory signals from multiple, widespread
brain regions. Notably, both glutamatergic (mainly from cortical regions) and
GABAergic innervation (predominately from CeA) drive the BNST but appear to
mediate different behavioral outputs. Indeed, inhibition of glutamatergic inputs to the
BNST results in a reduction of behavioral anxiety (Kim et al., 2013), whereas
GABAergic inhibition results in a disconnect in the feedback circuitry between BNST
and CeA that leads to decreased fear responses (Walker & Davis, 2008; Walker et al.,
2009). Alterations to either glutamate or GABA signaling could increase behavioral
responding to stressor exposure, which may be implicated in stress-induced reinstatement
to drug-seeking.

As mentioned above, the BNST receives strong noradrenergic signaling from several
BNST-adjacent brain regions, including the ventral noradrenergic bundle. NE-signaling
within the BNST could influence behaviors related to addiction, as shown in several
conditioned place preference and stress-induced reinstatement studies (Erb et al., 2000;
Wang et al., 2001). Indeed, complex associations exist between norepinephrine and
BNST

GABAergic

vs.

glutamatergic

signaling, but the role of norepinephrine
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in relapse remains unknown. Serotonergic and dopaminergic connections also innervate
the BNST, although have been shown to influence the rewarding aspects of drug taking
rather than the negative aspects. For example, cocaine administration increases
glutamatergic signaling at CRH receptors in the dorsolateral BNST (Kash et al., 2008)
and decreases inhibitory signaling in the BNST (Krawczyk et al., 2011), both which may
mediate the reinforcing effects of drugs of abuse. Similarly, serotonergic input from the
dorsal raphe nucleus (Phelix et al., 1992) could impact addiction-related behaviors.
Recently, Rainnie and colleagues (Guo et al., 2009) showed that stress alters the
expression of serotonin receptors in BNST neurons; since addiction and anxiety-related
disorders are often co-morbid, serotonin inputs may mediate behaviors associated with
different phases of addiction.

Similarly, several peptides have been shown to innervate the BNST and affect cellular
and circuit-based activity within the extended amygdala. In addition to CRH (discussed
above), neuropeptide Y (NPY), orexin and dynorphin also innervate the region and may
be involved in stress-induced relapse. Indeed, CRH infusion within the BNST facilitates
stress-induced relapse, but infusion of CRH antagonists attenuates reinstatement (Erb &
Stewart, 1999; Wang et al., 2006), and NPY involvement has been implicated in stressand anxiety-related behavior in mouse models (Pleil et al., 2012).

BNST efferent signaling
The BNST sends both inhibitory and

excitatory
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projections

to

several

addiction-related brain regions. Most notably, BNST sends GABAergic and
glutamatergic signals to the VTA, PVN, and regions of the hypothalamus, such that
several studies have shown increases in c-fos staining (a marker of neuronal activation) in
the BNST-VTA neural circuit following stressor exposure in a reinstatement paradigm
(Briand et al., 2010) and similarly increased c-fos levels in the lateral hypothalamus after
morphine withdrawal (Aston-Jones & Harris, 2004; Sartor & Aston-Jones, 2012)
indicating that some regions that receive projections from BNST may be involved in
components of addiction. Furthermore, projections to the PVN may be critical in
activating the HPA axis and, therefore, may be important in stress-induced relapse
processes. Indeed, the PVN receives GABAergic projections from the BNST (Dong et
al., 2001; Dong & Swanson, 2006), and several studies have shown that acute stressor
exposure (including acute cocaine injection) can increase CRH mRNA transcripts
(Rotllant et al., 2007; Hammack et al., 2009). Because CRH signaling plays such a
crucial role in activation of HPA axis after stressor exposure, we propose that BNST
neurons (specifically PACAPergic neurons) may synapse onto CRH neurons in the PVN
and induce stress-related behavioral responses. In contrast to this idea, several studies
have shown that acute stressor exposure does not alter PACAP transcript levels, so it may
be that chronic stress, or chronic drug-use, is necessary to activate PVN CRH. Indeed,
our laboratory has shown that chronic stress can increase PACAP and PAC1 receptor
transcripts in the PVN and BNST (Hammack et al., 2009), and we know that PACAP
infusions directly into the BNST can mimic behavioral effects of chronic stressor
exposure (increased startle responses; anxiety-like behaviors on elevated plus maze and
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open field tests for anxiety; anorexic-like behaviors; increased corticosterone levels;
Hammack et al., 2009; Roman et al., 2014; Lezak et al., 2014; Kocho-Schellenberg et al.,
2014). Importantly, these behavioral responses could all be attenuated by administration
of the PAC1/VPAC2 receptor antagonist, PACAP6-38.

BNST in the Dark Side of Addiction
Koob and colleagues (Koob & Le Moal, 2001; Koob & Le Moal, 2008; Koob, 2015;
Koob & Volkow, 2016) have proposed a hypothesis termed the “dark side of addiction”
and characterized by the development of negative emotional states that may lead to
negative

reinforcement

states

in

addiction-related

physiology,

behavior,

and

psychopathologies. From his work, two primary theories have emerged regarding the
neurocircuitry that leads to the negative affect (i.e. withdrawal) stage of addiction: a
within-system neuroadaptation due to drug use that lessens involvement of brain reward
systems, and a between-system neuroadaptation that increases the involvement of stressrelated brain systems, including regions of the extended amygdala such as the BNST.
Indeed, as withdrawal symptoms develop and progress, brain stress systems become
more prevalent than brain reward systems and include the activation of CRH (Koob & Le
Moal, 2001), norepinephrine (Carlezon et al., 2000), and PACAP (Miles et al., 2017)
peptides that drive negative emotional states. Hence, an increase in stress system
responding paired with a decrease in pleasure from reward systems provides substantial
motivation for abstaining drug users to reinstate drug-taking.
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The “dark side of addiction” may also drive an antireward system, such that
neuroadaptations may occur after drug use that serve to limit reward (Koob & le Moal,
1997; Koob & Le Moal, 2008). Indeed, Koob (2008, 2015) argues that brain stress
systems may be engaged to combat the negative effects of abusive drugs and help restore
the body’s homeostasis. As mentioned, both the HPA axis and extended amygdala brain
regions are altered by drug self-administration, and researchers have reported increased
levels of corticosterone, adrenocorticotropic hormone, and CRH during periods of
withdrawal (Heilig et al., 1994; Koob, 2009). In animal models, many of the behavioral
consequences of stressor exposure can be reduced by CRH antagonist administration
during withdrawal (Navarro-Zaragoza et al., 2010). Hence, anxiogenic-like responses in
elevated plus maze during withdrawal are attenuated with CRH antagonist administration
(Sarnyai et al., 1995); conditioned place aversion to drugs of abuse can be reversed with
CRH antagonists (Hand et al., 1988; Contarino & Papaleo, 2005); and reward thresholds
produced by drug withdrawals are reduced with CRH antagonist administration
(Bruijnzeel et al., 2010). Our lab and others (Tsukiyama et al., 2011; Hammack & May,
2014; Roman et al., 2014) have argued that PACAP may be upstream of BNST CRH and
therefore may play a prominent role in modulating an extra-hypothalamic CRH system
implicated in relapse. Prior work has demonstrated that PACAP6-38 ablates the
production of CRH mRNA: hence, upstream BNST PACAP may be necessary for the
activity of PVN CRH and other related stress-regions. Alternatively, drug-taking may
elicit a chronic stress response that activates PACAP in the PBn. May & colleagues
(Hammack & May, 2015; Missig et al., 2014) described the co-localization of PACAP
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and calcitonin gene related peptide (CFRP) in the PBn that extend to the BNST and
amygdala. Chronic relapsing episodes may also depend on this system, as
neurotransmitter systems implicated in stress-induced relapse appear to be reactivated
during periods of craving (See et al., 2003; Shaham et al., 2000; Koob & Le Moal, 2008),
further implicating the idea of an “antireward” system. Indeed, brain reward and stress
systems activated during periods of drug use are also active during withdrawal (a
between-system opponent process; Koob & Le Moal, 2008), producing anxiety and
irritability that comes with discontinued use (due to CRH activation in the extended
amygdala) and subsequently causing relapse.

Results of previous studies (Miles et al., 2017) are consistent with hypotheses suggesting
that stress systems have a role in the vulnerability to relapse following stressor exposure
(Koob & Le Moal, 2008); the BNST has been argued to play a key role in the antireward
system that may be upregulated by repeated administration of drugs of abuse (Koob & Le
Moal, 2008; 2001). Stressor exposure may promote relapse by activating some of the
same antireward circuits associated with withdrawal (Koob, 2015). As mentioned,
activation of central CRH systems has been suggested as a key step in the recruitment of
this antireward system by drugs of abuse (Koob & Le Moal, 2005), as PACAP may be an
upstream regulator of CRH in several stress-related regions such as the BNST. Prior and
current data suggest that BNST PACAP recruitment may also be a key feature of the
antireward system that sustains addiction and promotes relapse.
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To summarize, the negative reinforcement view of addiction proposes that drugs of abuse
simultaneously activate both brain reward circuits and antireward (stress) circuits that are
negative in value. As a result, the activation of central and peripheral stress responses
likely becomes a part of the context of drug taking, creating a “renewal” effect and
causing a relapse of responding when it occurs again after extinction has been conducted
in the absence of stressor exposure (the contextual hypothesis of stress-induced
reinstatement; for review, see Bouton et al., 2014; Schepers, 2017). BNST PACAP
activation may be a critical component of drug administration that becomes part of the
context of drug taking that can then produce renewal following extinction. Consistent
with this argument, cocaine has been shown to activate neurons in the BNST (Singewald
et al., 2003), and, as Miles et al. (2017) demonstrated, BNST transcript levels were
significantly increased by cocaine self-administration. Hence, BNST PACAP activation
may represent part of the context of cocaine self-administration that serves to renew
cocaine-seeking behavior after extinction.

Prior reports have suggested that activation of CRH receptors in the BNST, but not the
amygdala, mediates stress-induced reinstatement to drug seeking (Erb & Stewart, 1999).
At the circuit level, CRH release regulates BNST synaptic activity, both directly and via
interactions with noradrenergic systems (Kash & Winder, 2006; Nobis et al., 2011). The
role of BNST CRH and norepinephrine in processes related to addiction is complex and
may depend on the drug investigated, and it is still unclear how and whether BNST
PACAP interacts with these other BNST systems to produce the behavioral effects we
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and others have reported. As noted above, we and others have argued that PACAP is
upstream of BNST CRH activation and thus may be critical in mediating the effects of
stress on the reinstatement of extinguished drug-seeking behaviors.

Considerations from quantitative polymerase chain reaction (qPCR)
Miles et al. (2017) showed 10d of cocaine self-administration significantly elevated
BNST PACAP transcript levels, although PAC1, VPAC1, VPAC2, CRH, and VIP levels
remained unchanged. Interestingly, BNST PACAP transcript levels were not elevated by
the reinstatement footshock treatment; however, footshock may lead to peptide release
that is not reflected in changes in mRNA. We were surprised by the lack of increase in
CRH transcripts following chronic cocaine self-administration but maintain that upstream
PACAP release could enhance the excitability of BNST CRH neurons to promote CRH
release independent of changes in transcript. It may also be possible that BNST PACAP
targets a specific population of CRH neurons (Marcinkiewcz et al., 2016). We have also
previously reported that chronic stress upregulates BNST PAC1 receptor transcripts, but
not VPAC1/VPAC2 transcripts (Lezak et al., 2014; Hammack et al., 2009). Interestingly,
a recent experiment by Missig et al. (2017) showed that chronic pain elevated PACAP
transcript levels in the PBn, but not in CeA, BNST, or solitary nucleus (NTS).
Furthermore, acute stressor exposure or a single day of cocaine self-administration does
not appear to increase PACAP transcript levels (Figure 1.2; Miles et al., 2017; Lezak et
al., 2014) indicating that transcript levels may only rise after a period of sustained stress.
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Considerations from PACAP KO studies
PACAP and PAC1 knockout (KO) mice display numerous behavioral abnormalities,
including decreased social interaction (Ishihama et al., 2010), increased locomotion
(Hashimoto et al., 2011), decreased anxiety-related behaviors (Hashimoto et al., 2009),
anorexic tendencies (Nakata et al., 2004), and memory impairment (Hattori et al., 2012),
indicating a potential role for PACAP signaling in multiple mental disorders.
Interestingly, PAC1 receptor deficient mice have a normal stress response to acute
stressor exposure, but chronic stress resulted in heightened attenuation of HPA axis
activation (Mustafa et al., 2015). Hence, PACAP-PAC1 receptor signaling may occur at
later timepoints and require prolonged stimuli, such as chronic stressor exposure or
chronic drug-taking. Few, if any, studies to date have characterized the timing of PACAP
expression in a model of drug self-administration. However, the idea of a sustained
stimuli acting on the PACAP system corresponds with data showing that only chronic
stressor exposure increases BNST PACAP transcripts (Hammack et al., 2009; Lezak et
al., 2014), and PAC1 receptor endocytosis may be facilitating downstream signaling
cascades and “holding on” to PACAP molecules to create a sustained physiological
response.
6.2. BNST PACAP signaling via ERK

Signaling through extracellular signaling related kinase (ERK) activation
In reward-related brain regions, activation of ERK transcriptional pathways and
subsequent neuronal adaptations lead to

cocaine-induced
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behavioral

plasticity

(Girault et al., 2007; Valjent et al., 2006). Hence, in the nucleus accumbens and striatum,
cocaine exposure increased pERK in rats who were cocaine experienced, indicating a
sensitization by prior drug administration (Yoon et al., 2007; Valjent et al., 2000).
Consistent with these results, we found an increase in pERK cells in the BNST after 10d
drug self-administration followed by footshock stress. Interestingly, the heightened levels
of pERK likely resulted from footshock stress, but only occurred in animals who were
cocaine experienced, indicating a sensitization of the PACAP/PAC1 system in response
to cocaine. Furthermore, the presence of ERK signaling on test day (after 20d of
extinction training) suggests that ongoing ERK signaling in the BNST is related to
prolonged exposure to a stimulus (10d drug-taking) rather than part of the initial
plasticity that results from acute stressor exposure or 1d cocaine taking (what we might
see in cocaine non-responders after footshock stress and vehicle treatment, for example).
These studies also found evidence that PACAP signaling may mediate BNST ERK
activation. Indeed, May and colleagues (May et al., 2010; Hammack & May, 2015; May
& Parsons, 2017) showed that PACAP signaling in HEK EGFP-PAC1R cell culture
results in elevated ERK activation, and Missig et al. (2017) showed that, in the CeA,
ERK activation occurred in close proximity to PACAP-immunoreactive fibers.
Furthermore, intra-CeA PACAP infusion resulted in an increase of pERK cells,
indicating that PACAP signaling activates pERK in amygdala neurons. Additional
studies are needed to observe the effect of intra-BNST PACAP infusion on pERK
expression, although the current studies suggest that prolonged stressor exposure and
subsequent pERK activation is necessary for stress-induced reinstatement. Hence, we
125

would anticipate an increase in BNST pERK following PACAP or maxadilan infusion.
Additional studies here showed that pERK activation is necessary for footshock stress to
reinstate drug-seeking behaviors, as pretreatment with MEK inhibitor PD98059 or
clathrin-mediated endocytosis inhibitor Pitstop2 reduced stress-induced reinstatement.

Importantly, BNST ERK signaling is likely the site of convergence for multiple peptide
signaling systems in the extended amygdala, as several other signaling events likely play
a role in PACAP- or stress-induced behavioral and physiological responding, including
norepinephrine, dynorphin, orexin and CRH. Here, we suggest that PACAP activates
ERK through the internalization of PACAP receptors. As mentioned, Merriam et al.
(2013) demonstrated that PACAP/PAC1 receptor binding induces PAC1 receptor
internalization which can be blocked using clathrin-mediated endocytosis inhibitor
Pitstop2 or dynamin I/II inhibitor, dynasore, resulting in diminished ERK activation.
Here, we extend these findings in a stress-induced reinstatement paradigm in vivo and
show diminished pERK activation after pretreatment with MEK and endocytosis
inhibitors. This compliments work done by Missig et al. (2017) demonstrating a possible
functional role of PAC1 receptor internalization in CeA pain circuits. However, in both
chronic pain and chronic drug self-administration models, we must be critical of the
Pistsop2 pretreatment, as endocytosis inhibition is not selective to the PAC1 receptor and
globally inhibits receptor endocytosis in the region of infusion. In the absence of
endocytosis inhibition, PAC1 receptor internalization may present a means for sustained
ERK activation and subsequent long-duration behavioral and physiological effects of
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PACAP-PAC1 receptor binding.

ERK activation via AC or PLC
PAC1 receptor endocytosis is not the only mechanism by PAC1 receptors stimulate ERK
phosphorylation. Indeed, differing PAC1 receptor isoforms can be coupled to Gαs or Gαq
to activate adenylate cyclase (AC) or phospholipase C (PLC), respectively (for review,
see Hammack & May, 2015). Hence, there are other means by which PAC1 receptor
activation may mediate the behavioral consequences of stressor exposure. Indeed, both
drugs of abuse and stressors exert their effects on neurons through a cascade of
intracellular signaling events (including AC and PLC) that leads to increased calcium
levels and stimulation of protein kinase C (PKC). Notably, chronic morphine
administration has been shown to increase activation of the PLC signaling cascade, likely
by direct action of neurotrophic factors (Bolanos & Nestler, 2004), but the functional
consequences of PLC activation by chronic drug administration are not well understood.
However, PLC activation could conceivably contribute to drug-induced neuroplasticity in
reward-related regions. Since there was no change in pERK expression in cocaine
responders who received vehicle vs. Pitstop2 treatment with or without footshock
exposure, we can infer that PAC1 receptor internalization is required for BNST PACAP
signaling to induce ERK phosphorylation and activate stress-related behavioral responses
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6.3. Relation to human studies and clinical trials
Several studies have reported that during abstinence from drug use, stress exposure often
occurs in the presence of contextual cues that had previously been associated with drug
use (Epstein et al., 2009); these cues may cause an initial lapse in abstinence.
Additionally, in a similar manner to the drug-cue induced reinstatement (better termed
“renewal”; see Bouton, 2014), human studies have indicated that stressor exposure can
lead to cue-induced drug craving (Moran-Santa Maria et al., 2015; Fox et al., 2014;
Mantsch et al., 2015). Furthermore, Sinha and colleagues (1999; 2001) introduced a
clinical trial based on the rodent stress-induced reinstatement paradigm. In these trials,
stressor exposure (guided imagery stress and Trier Social Stress Task) caused increased
drug craving. Additionally, researchers provided a systemic CRH injection to induce
physiological (i.e. increased cortisol release) and psychological (i.e. increased anxiety)
stress responses. Since then, many researchers have examined the effects of different
drugs on stress-induced relapse (Sinha et al., 2007; Fox et al., 2012; McKee et al., 2014;
Moran-Santa Maria et al., 2015), but none have observed the potential effect of PACAP
on stress-induced relapse.

PACAP treatments may locally target BNST PAC1 receptors via systemic injection to
antagonist receptors and prevent PACAP binding that facilitates stress-related responses
and, subsequently, stress induced relapse to drug seeking. By blocking BNST PACAP
activation, PVN CRH activity may be modified, altering responses to stressor exposure.
Continued research of mechanisms that underlie stress- and drug-cue-induced
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reinstatement after a period of abstinence may lead to the development of viable
treatments for relapse prevention.

As mentioned, the limited data in human drug abusers indicate a reliable correlation
between animal models of reinstatement and drug relapse and craving in humans. As
research in the field of drug abuse continues, it will remain important to develop practical
(medication development) and theoretical models to combat substance use. Future
laboratory-based human models may mimic and complement existing laboratory-based
rodent models. The potential use of PACAP antagonists as a method to prevent stressinduced relapse during times of known stressor exposure should be considered. Indeed, it
will remain important throughout these developmental phases to investigate the
concordance between human and animal data of stress-induced relapse.

6.4. Summary
PACAP has been widely accepted as a critical neuropeptide in regulating homeostatic
function, particularly in response to stressor exposure. Indeed, PACAP signaling can
activate both physiological and behavioral responses to stress. PACAP may, therefore,
have roles in drug-taking processes, as several phases of addiction have been shown to
activate stress response systems. In this dissertation, the role of PACAP-PAC1 receptor
activation was investigated in a stress-induced reinstatement paradigm.

The results of this work and the work of

Miles
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et

al.

(2017)

raise

several

additional questions. As discussed above, we found heightened levels of PACAP
transcript in animals who received 10d cocaine, but not in animals who only received a
single infusion of cocaine. Furthermore, after a period of extinction, footshock exposure
failed to elicit an increase in PACAP transcript, indicating that PACAP transcript levels
may return to control levels following a period of extinction. Here, we found that
maxadilan infusion recapitulated previous findings and mimicked stressor exposure to
increase drug-seeking in a test for reinstatement, but the time course for
PACAP/maxadilan actions on PAC1 receptors is unclear. Hence, future studies might
seek to determine whether the same signaling events mediating reinstatement (i.e. PAC1
receptor endocytosis and MEK activation) mediate stress-induced increases of pERK at
different stages of acquisition and extinction in addition to reinstatement. Furthermore,
we determined the downstream signaling events mediating stress-induced reinstatement
to drug seeking, but whether the same activation occurs in response to PACAP-induced
reinstatement is unknown. Additionally, we hypothesize that PACAP-induced increases
in pERK expression occurs on CRH neurons within the oval nucleus of the BNST, but
the location of PAC1 receptors mediating the effects were see in this dissertation are
unclear. Also unclear is the source of BNST PACAP. Hence, future studies may aim to
determine where BNST PACAP originates, and how its actions within the oval nucleus
facilitate reinstatement to drug seeking. The use of PACAP-cre or CRH-cre mice could
be a powerful tool to answer some of these questions. Indeed, injection of a credependent virus into the BNST may help us determine which neurons respond to PACAP
or CRH (respectively) in a test for PACAP- or stress-induced reinstatement.
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This work demonstrates the involvement of PACAP-PAC1 receptor activation in stressinduced reinstatement to drug seeking. Indeed, through the PAC1-endocytosis-MEKpERK pathway, PACAP seems to potentiate some of the behavioral consequences related
to stressor exposure after a period of drug-taking. Importantly, the molecular targets
involved in addiction and relapse and just now being thoroughly investigated. However,
continued work in this area may explain how circuits become dysregulated, and stay
dysregulated, in response to stress or drug use to facilitate psychiatric disorders like
addiction, PTSD, anxiety, and other stress-related disorders. Ultimately, the
neurobiological targets uncovered through research such as these dissertation
experiments may identify novel targets for relapse prevention.
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